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Small molecule synthesis has become a valuable tool in the study of biological systems. 
Biologically active compounds can be designed based on well-characterized endogenous systems 
or they can be found through the screening of large libraries of small molecules. This work 
involves the development of a small library of cyclic thiourea-based small molecules by use of 
an unreported synthetic pathway. Briefly, parent thioureas were cyclized by reaction with 
bromoacetyl bromide, and one or two isomeric heterocycles were found to form. Further studies 
indicated that the reaction could be easily manipulated by temperature or solvent to effectively 
control the product distribution. These iminothiozolidinones were characterized by single crystal 
xiv 
 
x-ray analysis. The new reaction was explored in an effort to uncover the factors influencing the 
control of the isomer formation. Furthermore, these iminothiozolidinones underwent a novel 
decyclization reaction that resulted in the loss of the parent thiourea connectivity and 
incorporation of an external nucleophile to yield an aminooxoethylcarbamothionate. The reaction 
proceeds through a termolecular mechanism. These reactions can be combined to a one-pot 
reaction series. These compounds share similarities with a class of compounds reported to be 
known HIV-1 reverse transcriptase inhibitors
94
. In addition to these new synthetic reactions, 
work was conducted with a previously developed cyclen thiourea receptor for the anionic dye 
HPTS and its derivatives
50-52
. This system was used to develop a cell labeling assay that led to 
the amplification of fluorescent labeling of target cells through the use of liposomes. Briefly, a 
dye-ligand conjugate for the glycine receptor was synthesized. Liposomes functionalized with 
the cyclen receptor were prepared encapsulating Rhodamine B. Confocal microscopy studies 
demonstrated the binding of the HPTS-ligand to the cell membranes. Addition of the liposomes 
resulted in quenching of the green fluorescence, indicating binding of the cyclen to HPTS. 
Subsequent excitation of Rhodamine B showed red fluorescence associated with the cells. The 
intensity of the red signal was demonstrably higher than for the signal resulting from the binding 
of the ligand-dye to the receptor. Together, these projects increase the synthetic usefulness of 
thiourea based small molecules and demonstrate the potential biological applications of related 
compounds. 
 
  
 
 
 
Chapter 1. 
 
 
Introduction 
 
 
1.1 Fluorescent Imaging of Cells 
 
 
Fluorescent imaging of cells has been a technique used for many years and is useful for 
studying many diverse targets.
1
 A common approach is to fluorescently tag a ligand through 
covalent bonding to a fluorophore and apply the dye-conjugate to a cell culture.
2
 The ligand 
would bind to the cells expressing the target, and these cells can then be excited and imaged 
using confocal microscopy. Many different components of a cell can be labeled, including DNA 
sequences. For example, the FISH assay can be used to fluorescently label cells that express 
target RNA strands through tagged DNA and therefore diagnose the presence of disease 
markers.
3,4
 This assay is done in collected cells and requires an hour or more hybridization time. 
Alternatively, ELISA assays are very effective in searching for markers from cell lysate 
samples
5
.  
Vascular endothelial growth factor (VEGF) is responsible for providing an adequate 
oxygen supply to tissues when there is minimal blood circulation.
6
 Tumors overexpress VEGF so 
that they can grow and metastasize. This makes VEGF a useful biomarker for the detection of 
cancer in blood serum.
7
 The traditional method of detection for VEGF is an ELISA protocol, 
however this requires a large sample volume and the use of antibodies.
8,9
 A new development in 
the detection of VEGF is the use of aptamers to recognize VEGF. Because aptamers bind one to 
 
 
2 
 
one, there needs to be a method for increasing the signal for enhanced sensitivity. After 
recognition of the target, DNA can be replicated, providing the amplification. The DNA-dye 
probe is then added, and fluorescence indicates presence of the cancer biomarker.
7
  
Regardless of which part of a cell is targeted, most techniques rely on the introduction of 
a fluorophore. Methods of labeling to be done in vivo require a shorter time scale. This can be 
achieved by tagging the ligand, which binds immediately, rather than having to wait for the 
hybridization to occur. The field of real-time imaging has seen a number of advances recently, 
allowing long-standing questions to be answered.
10,11
 The discovery of protein-based 
fluorophores has been instrumental to this growth. Fluorescent proteins, such as GFP, can be 
introduced to a protein target through genetic engineering.
12
 The advantage to this method is that 
movement of a fusion protein product can be monitored via the fluorescent protein. Although 
GFP has become a powerful tool for the study of proteins, the fluorescent protein approach limits 
the fluorophore that can be used, as it must be genetically encoded, and depending on the size, it 
might cause deviations from wild type behavior.
13,14
 Modern approaches have combined genetic 
engineering and the use of synthetic fluorophores. As an example, the SNAP-tag technology has 
become a widely used method to couple a protein of interest with a synthetic probe, such as a 
fluorophore, through the covalent bond formation between the tag and benzylguanine 
derivatives.
15-17
  
 
1.2 Single Molecule Probes for Real-Time Imaging 
 
 
 Fluorescence microscopy is used in innumerable ways by modern biochemists for the 
study of biological systems. Activities that can be studied include the detection of a specific 
DNA sequence responsible for gene expression, visualization of organelles, and cell tracking.
13
 It 
 
 
3 
 
is a necessary tool in modern research and has recently seen significant advancements. Indeed, 
the 2014 Nobel prize in Chemistry was awarded to Betzig, Hell, and Moerner for the 
development of super-resolved fluorescence microscopy, or nanoscopy.
18-22
 The wide-spread 
availability of these microscopes has led to the emergence of fluorescence detection of tumors 
during surgery as a means to getting better margins in removal of cancerous tissue. Since many 
cancers require the excision of tumors as the best path to a cure, and since it is necessary to 
minimize the removal of healthy tissue (especially if the tumor is in a sensitive area such as the 
brain) it is imperative that fluorescent imaging techniques for this purpose are fast, specific, and 
have a high signal compared to non-targeted tissue.
23,24
  
 There are two main modes for fluorescent imaging of tissue to guide surgery. The first is 
the use of endogenous fluorophores. This method relies on the fact that cancer cells 
autofluoresce more than healthy tissue.
25
 The main benefit with this approach is that it does not 
require the addition of any other agent, which would have to be approved after time-consuming 
and costly clinical trials. This also makes it a potential tool for diagnosis.
26
 The major drawback 
to this method is the low signal of tumor to background tissue ratio. 
 The other technique requires the use of exogenous fluorophores, or fluorophores that are 
applied to the system. This is advantageous because there are many biocompatible dyes that 
fluoresce at a high intensity, and the emission range can be selected. There are a number of 
probes already approved for fluorescence guided surgery. The biggest challenge in this method is 
the need to target these fluorophores to the specific group of cells to be removed without any 
other labelling of healthy tissue.
23,24
  
 Antibodies can be used to provide specificity to a target. Direct immunolabeling comes 
from linking a primary antibody to a fluorophore. This is advantageous because small molecule 
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organic dyes will likely not perturb the system to the extent that a larger fluorescent protein 
might and compounds are available that cover a range of wavelengths. This would make them 
useful in multiplexed imaging. The biotin-streptavidin system is another powerful tool to provide 
specificity between a probe and a target.
14
  
 
1.3 Use of Nanotechnology in Theranostics 
 
 
An important characteristic of any fluorophore is excitation and emission at ranges that 
are different from the biological environment (in the body or a cell growth medium). It should 
also have a high molar absorption coefficient and quantum yield as well as be biocompatible. It 
should be easily conjugated to a probe of some kind such as DNA, peptides, streptavidin or other 
protein ligand for use in targeted imaging,.
27
 Organic dyes are the classical choice of 
fluorophore, as they are cheap, readily available, and already approved for in vivo studies. 
However quantum dots such as CdSe and CdTe are becoming more common in biosensing.
28,29
 
The optical properties of quantum dots are in part controlled by their size, so a range of different 
potential fluorophores can be synthesized with relative ease.
30
 Because nanoparticle synthesis 
often already requires organic capping agents, the surface of quantum dots can be modified to 
bind to a targeting probe.
31-33
 This is also how their dispersion in water can be controlled.
34
 
Quantum dots generally exhibit more favorable optical properties while organic dyes are more 
easily incorporated into the cell and do not face issues with aggregation. For the labeling of cell 
surfaces, however, quantum dots have been successfully used by functionalization with 
antibodies specific for cell membrane receptors.
35-37
 Another potential advantage in the use of 
nanoparticles is that they often exhibit some biological activity and may be used as both an 
imaging agent and a therapeutic.
38-40
 As with any method, the specific needs of the particular 
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system in question will define the limitations of an experiment and subsequently dictate the 
choice in fluorophore. 
 Liposomes have long been used as a means to deliver drugs or imaging agents to a 
targeted system.
41-43
 Liposomes, a self-assembled lipid bilayer vesicle with an aqueous core, are 
biocompatible and easy to synthesize encapsulating any desired compound. The lipid bilayer 
may also be embedded with a compound of interest, letting both hydrophilic and hydrophobic 
agents be used.
44
 Liposome-nanoparticle hybrid development is another growing field. One such 
system involves the formation of liposomes encapsulating a drug with quantum dots that 
partition into the lipid bilayer. This system is used for both imaging from the quantum dots as 
well as drug delivery, which has been the traditional role of liposomes.
45-47
 
 
1.4 Thiourea Chemistry: Synthesis and Applications 
 
 
Thiourea and thiourea derivatives have a long history of both industrial and medicinal 
applications. Each year, around 8,000 tons of thiourea is produced for use in textile modification, 
photography, production of flame-retardant polymers, and in removing mercury from water.
48-50
 
Thiourea is a versatile precursor that allows for the inclusion of sulfur into different scaffolds. 
The presence of this sulfur contributes to the thermal stability and metal-binding properties of 
these different materials. Thiourea is a synthetically versatile precursor; it tautomerizes into 
isothiourea, shown in Scheme 1.1., and it participates in a number of different reactions.  
 
 
 
Scheme 1.1: Tautomerism of thiourea into isothiourea. 
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Substituted thioureas can be synthesized through a number of simple, high-yielding reactions 
using a range of different starting materials. A few selected examples are shown in Scheme 
1.2.
48,51
 The ease of formation from a variety of precursors makes this class of compounds 
readily accessible which has led to a wide variety of compounds that have found applications in a 
number of diverse areas (Figure 1.1). Some of those applications include use as antifungal 
agents,
52-55
 herbicides,
56
 and as a rodenticide.
57
 Functionalized thioureas may act alone or bind 
metals such as Ni(II), Pt(II), or Cu(II) when exhibiting activity. In the past ten years, these 
compounds have seen a rise in applications for treatment of HIV as reverse transcriptase 
inhibitors, as with Trovirdine (PETT) and Trovirdine analogs.
58-62
  
 
Scheme 1.2: Different reactions to form substituted thioureas. (A) Shows the formation of di- or 
tri-substituted thioureas. (B) Shows the formation of aryl-substituted thioureas, and (C) shows 
the formation of asymmetric di-substituted thioureas.
48
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Figure 1.1: Examples of selected biologically active thioureas. 
 
Substituted thioureas can act as both hydrogen bond donors and acceptors. Thioureas have 
also been seen to play a role in metal-free organocatalysis through hydrogen bond interactions.
63
 
The variety of reactions to form them as well as ones in which they act as a precursor make this 
class of compounds a synthetically interesting one. They are relatively stable in biological 
systems as they are neutral and not a target for common enzymes such as esterase. This makes 
them useful as a linker moiety for potential drugs. This also means that they are easily 
customized. It is this synthetic versatility that led to the use of functionalized thioureas in our 
group’s work in developing a method of selective cell labelling and amplification. 
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Chapter 2. 
 
 
Liposome-based Amplification of Cell Labeling Using a Cyclen Thiourea Receptor and 
Pyranine 
 
 
2.1 Development of the Cyclen Thiourea Receptor 
 
 
Previous work in the Sidorov group has focused on the development of a macromolecular 
complex that reversibly binds the class of sulfonated pyrene based dyes.
64-66
 This macromolecule 
consists of a cyclen core that has been modified to include four thiourea-based arms bound to the 
core through the amine groups (Figure 2.1). These arms consist of ester linkages, a thiourea 
moiety and terminate in aromatic groups. All of these regions are suspected to be involved in the 
binding of pyranine. Much work was conducted by the Sidorov group to characterize the 
selectivity and affinity of the receptor, cyclen 1, to the sulfonated pyrene dyes.
64,67
 Binding of 
cyclen 1 to HPTS, shown in Figure 2.2, results from a combination of hydrogen bonding 
between the thiourea groups with the sulfonate groups as well as π-π stacking between the planar 
body of pyrene and the naphthalene groups that terminate the arms. Additional stabilization 
comes from the interaction of a Na
+ 
ion with the ester bonds. It had been shown previously that 
the tetraester cyclen compounds will form this upright conformation in the presence of sodium 
ions.
68,69
 HPTS and the related dyes exist as trisodium trisulfonate salts, thus Na
+
 will always be 
present in the form of the counter ion. 
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Figure 2.1: Structure of the synthetic cyclen thiourea receptor, cyclen 1. 
 
 
Experiments were done to show that all elements of the receptor are necessary for 
binding and quenching the dye.
64
 When HPTS was mixed with a solution of either cyclen tetra-
NH-boc or the free ester arm monomer (Figure 2.3), there was no change in the fluorescent 
emission. The formation of the complex was further characterized by isothermal titration 
calorimetry and fluorescence titration studies.
64,67
 The titrations were carried out in PBS (10 mM 
sodium phosphate, 100 mM NaCl, pH 6.4) and were used to determine the Ka of cyclen 1 
binding HPTS, APTS, and PTA. The cyclen receptor was able to quench over 90% of the 
fluorescence of each dye.  The structures of the dyes that bind and their Ka’s are given in Figure 
2.4. Studies were also done to show the selectivity of the cyclen receptor for sulfonated pyrene 
dyes over other dyes such as 5-CF, 6-CF, and calcein which are anionic but non-planar, and 
safranin O, which is cationic. The isothermal titration calorimetry studies, reproduced in Figure 
2.5, were carried out in methanol and found that cyclen 1 binds to pyranine in a 1:1 or 1:4 
HPTS/receptor binding mode. The envisioned 1:1 mode is shown in Figure 2.2. As stated, the 
binding comes from a combination of interactions 
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Figure 2.2: Envisioned binding mode of cyclen 1 and pyranine dye. The back arms are truncated 
for clarity.
64
 Reprinted with permission from Winschel, C. A.; Kalidinid, A.; Zgani, I.; 
Magruder, J. L.; Sidorov, V. Receptor for Anionic Pyrene Derivatives Provides the Basis for 
New Biomembrane Assays. J. Am. Chem. Soc. 2005, 127, 14704-14713. Copyright 2005 
American Chemical Society 
 
 
 
 
 
Figure 2.3: Structures of receptor control compounds. These were used to test the necessity of 
different elements in the complex formation between the cyclen receptor and pyranine. (A) 
Cyclen tetra-NH-boc and (B) the naphthyl thiourea arm monomer. 
 
 
between the dye and the receptor, with the π-π interactions being the most important. This 
complexation appears to be driven by the solvophobic effect. When mixed in methanol or 
aqueous solutions, the insoluble complex forms and binding is quenched. However, binding is  
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Figure 2.4: Structures of dyes that are bound by cyclen 1: Ka was measured by fluorimetric 
titrations using 50 nM solutions in PBS (10 mM sodium phosphate, 100 mM NaCl, pH 6.4)  
 
 
 
Figure 2.5: Microcalorimetric characterization of interactions of cyclen 1 with pyranine and 
calcein in methanol: (A) Raw data for the titration of a 0.25 mM solution of pyranine with a 10 
mM solution of cyclen 1. (B) Integrated data from (A), corrected by the heat of cyclen 1 dilution, 
normalized to moles of injectant and plotted as a function of cyclen 1/pyranine ratios (solid 
squares). A continuous line represents the data fit in two sets of sites binding model. (C) Raw 
data for the titration of a 0.25 mM solution of calcein with a 10 mM solution of cyclen 1. Note 
the difference in vertical scales for plots (A) and (C). (D) Integrated data from (C), corrected by 
the heat of cyclen 1 dilution, normalized to moles of injectant and plotted as a function of cyclen 
1/calcein ratios.
64
 Reprinted with permission from Winschel, C. A.; Kalidinid, A.; Zgani, I.; 
Magruder, J. L.; Sidorov, V. Receptor for Anionic Pyrene Derivatives Provides the Basis for 
New Biomembrane Assays. J. Am. Chem. Soc. 2005, 127, 14704-14713. Copyright 2005 
American Chemical Society. 
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not observed in DMSO or acetonitrile.. The 1:4 HPTS/receptor binding is weaker by two orders 
of magnitude and relies primarily on electrostatic interactions and hydrogen bonding.   
2.1.1 Lipid Flip Assay 
 
 
The cyclen receptor was used in an assay to monitor lipid flip.
65
 Lipid flip can be 
controlled by enzymes such as flippases, floppases, and scramblases.
70
 Proper function of these 
enzymes is important for maintaining cell membrane composition and lipid flip is part of a 
number of processes such as apoptosis and blood clotting.
71-77
 Although there are several known 
methods to monitor lipid flip in membranes of cells or model systems, these have certain 
disadvantages.
78-80
 The NBD-dithionite assay involves the use of NBD labeled lipids that are 
introduced into liposomes or cells. The fluorescence of NBD is then quenched with 10-60 mM 
sodium dithionite (Na2S2O4) through the reduction of the nitro group to the amine. The two 
major drawbacks to this method are the high concentration of sodium dithionite that is required 
to quench the fluorescence, as well as the fact that this quenching is irreversible, Additionally, it 
is possible that the sodium dithionite, which is a small anionic salt, may be taken up into the cell, 
which would lead to quenching both inside and outside the cell. 
The pyranine-cyclen 1 receptor system was modified for use in an assay to monitor lipid 
flip in both liposomes as well as in vitro studies. DOPE labeled with HPTS (known as cascade 
blue) was synthesized and incorporated into the membranes. Previous work had shown that 
cyclen 1 is not cell permeable.
64
 and it was later shown that it does not inhibit cell growth. When 
10 uM cyclen 1 was added to the solution of liposomes, the fluorescence decreased by 43%, 
indicating that the fluorescence from outer-facing cascade blue was quenched while the cascade 
blue facing the inside of the liposome remained. The addition of porcine liver esterase resulted in 
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the restoration of fluorescence up to 90% of the original intensity. This demonstrated that the 
pyranine-cyclen 1 system was suitable for monitoring lipid flip, and that the quenching 
interaction was reversible. Similar results were found when the cascade blue lipid was incubated 
with HEK 293 cells and a solution of 20 uM cyclen 1 was added.  
 
2.1.2 Chemoselective Precipitation Assay 
 
 
One of the characteristics of the complex that forms between the cyclen 1 receptor and 
pyranine dyes is the formation of an insoluble complex in aqueous and methanolic solutions. 
This is true even though both compounds when isolated have a degree of solubility in the two 
solutions.  This led Kaushik et al to develop a chemoselective precipitation assay based on the 
cyclen 1 receptor and APTS.
66
 Using this method, they were able to isolate lactose from a 
mixture of sucrose and lactose using the following protocol. APTS was added to a solution (1:9 
H2O:MeOH) of lactose and sucrose. Because lactose has a reducing end and APTS has the amine 
function on the ring, the two compounds could undergo reductive amination selectively in the 
presence of sucrose. A solution of cyclen 1 receptor was added and the resulting precipitate was 
collected. Back extraction with chloroform released the complex and APTS labeled lactose. 70% 
of the sucrose was recovered in this manner.  
This method, however, required the formation of an irreversible bond between the APTS 
and lactose. This protocol was further refined to allow the separation of the two sugars with 
reversible binding to the dye. 1 M acetic acid was used to cause the formation of the imine bond 
between APTS and lactose. Cyclen 1 was then added to form the precipitate and this was 
collected as before. The precipitate was hydrolyzed with 2 M acetic acid. The solvent was 
removed after 2 hrs and the solid residue was treated with 1 N aqueous ammonia and then back 
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extracted with chloroform to give the cyclen 1 receptor in the organic layer and APTS and 
lactose in the aqueous layer. The lactose could be further purified by the addition of cyclen 1 to 
remove the free APTS. This method led to the purification of lactose from the solution with 
recovery of the cyclen receptor and APTS, but due to the reversible nature of imine formation, 
the sucrose was not entirely purified of lactose. However, each of these two methods led to 
purification of one of the sugars, demonstrating the usefulness of this system for chemoselective 
precipitation as a purification scheme for mixtures of sugars which would otherwise be difficult 
to separate.
81,82
 
 
2.1.3 Modification of the Cyclen Receptor 
 
 
Following this work, cyclen 2 was developed.
67
 This compound is a variant of cyclen 1, 
in which the cyclen core contains a p-nitro-benzoyl group. The arms were conjugated to the 
cyclen group and the nitro group was reduced to an amine (Scheme 2.1). This variant binds to 
the pyrene based dyes in the same fashion but also contains a site that can be easily modified. 
Cyclen 2 was developed so that the cyclen receptor could be conjugated for further use. For this 
work, the cyclen receptor was conjugated to palmitoyl chloride to form the cyclen receptor lipid 
(Scheme 2.2). 
 
 
Scheme 2.1: Synthesis of cyclen 2 receptor. Reduction of the cyclen receptor using Sn and HCl 
to form cyclen 2. 
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Scheme 2.2: Synthesis of the cyclen receptor lipid. This lipid was synthesized using cyclen 2 
and palmitoyl chloride. 
 
 
2.2 Experimental Design 
 
The fact that this receptor is both easily modified as well as biocompatible led us to 
design a cell imaging assay dependent on the selective binding of HPTS to cyclen 1. We chose a 
cell-membrane receptor to study based on several criteria. First, the receptor needed to be a 
ligand-gated ion channel (LGIC). This is a large class of cell-membrane receptors that are 
responsible for a number of diseases including epilepsy, autism, and alzheimers.
83-86
 We chose 
this class so that potential ligands could be studied via the patch-clamp technique.
87
 Patch-clamp 
is a method that measures the voltage generated when a ligand binds to a LGIC. The voltage 
comes from the flow of ions which is triggered by the binding of the ligand to the receptor. The 
proof of concept experiment was developed by conjugating HPTS to a ligand capable of binding 
to a LGIC, GlyR, and preparing liposomes functionalized with the cyclen receptor and 
encapsulating a second dye, Rhodamine B (Figure 2.6). The glycine receptor (GlyR) is a ligand-
gated ion channel that is activated by endogenous glycine.
88,89
 The dye-ligand conjugate would 
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bind to the receptor when applied to the cells and fluoresce green. The liposomes, when added, 
would quench the dye via cyclen 1 binding to the HPTS moiety, and the second dye could be 
excited, leading to fluorescence associated with the cells and a greater intensity, up to a million 
fold amplification. 
 
 
 
Figure 2.6: Liposome-based amplification of cell labeling. The method relies on the formation 
of a ternary complex between the cell, dye-ligand conjugate, and cyclen receptor conjugated 
liposomes. 
 
 
2.3 Target Choice: α1GlyR as a Model System 
 
 
Cells express many diverse proteins on their membranes. Many of these proteins act as 
channels to allow the flow of molecules and ions into or out of the cell, since most cannot freely 
pass through the dense, hydrophobic lipid bilayer.
90
 Others play roles in complex signaling 
pathways.
91,92
 Membrane proteins may be present in small amounts, or they may be highly 
expressed. Changes in the expression levels of proteins are often characteristic of disease 
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phenotypes. For example, VEGF is largely undetectable in healthy neuronal cells, but is over-
expressed in cancerous cells, and participates in angiogenesis of gliomas.
6,93,94
 Autosomal 
dominant polycystic kidney disease is another common genetic disease characterized by 
overexpression of a membrane protein, PKD1.
95
 
Ligand gated ion channels comprise a diverse class of membrane proteins. These 
channels control the flow of ions through the lipid bilayer in response to physiological events.  
Activation occurs when a specific molecule, the receptor’s ligand, binds to the activation site of 
the receptor, inducing a conformational shift. This change in conformation opens a channel for 
ions to travel through. Diffusion may be passive or active, depending on the direction of the 
gradient.
96
  
This particular study focuses on the glycine receptor (GlyR), which is a ligand gated ion 
channel that is found in the central nervous system, specifically the spinal cord, brainstem, and 
cerebellum, as well as retinal tissues.
88,89
 These receptors control the flow of chloride ions into 
the cell. They are activated by L-glycine, an inhibitory neurotransmitter, but can also be 
allosterically modulated by many chemicals such as ethanol, Zn(II), and other endogenous amino 
acids such as taurine. GlyRs are prevalent in nervous tissue, but they can be composed of 
different combinations of α and β subunits. The composition of subunits determines the 
characteristics of the receptors. All of them, however, are activated by glycine and are important 
in maintaining intracellular Cl- balance. Activation of these receptors results in 
hyperpolarization, when the Cl- ions enter the cell due to the extracellular concentration of Cl- 
being higher than the intracellular concentration.
97
  
Properly functioning GlyRs are necessary for many biological functions such as 
voluntary motor control, reflex responses, and sensory input. Certain mutations cause the GlyR 
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to be less sensitive to glycine by up to 100 fold, and this results in what is known as 
hyperekplexia, or startle disorders. These diseases are characterized by heightened responses to 
startlement followed by muscle stiffness. It has been characterized in humans, cows, and 
mice.
98,99
 Others have suggested that GlyRs are involved in pain perception, autism, and 
epilepsy.
83-85
 Furthermore, these receptors are known to interact with other receptors such as 
GABA and NMDA, suggesting the GlyR plays a large role in neuronal homeostasis.
97
 Despite all 
this, there is still much unknown about glycine receptors such as their composition in different 
tissues and many of their roles may still be unknown. Thus GlyR may become an important 
therapeutic target, and any further characterization of the receptor is valuable. 
In addition to the GlyR being a good target for functional studies, it also makes an ideal 
candidate for development of enhanced visualization methods. As a ligand gated ion channel, its 
ligand binding can be well-characterized by patchclamp techniques, and extracellular binding 
ligands means that a fluorescent labeling technique could be a good way to visualize cells with 
specificity. This could be used to detect the presence of cells, such as cancer cells, that need to be 
removed fully during a surgery. However, if there are only a small number of cells present, 
visualization in an in vivo situation would require increased sensitivity.
93
  
The aim of this work was to take advantage of the ligand-receptor interaction to provide 
specificity to a target, in this case cells expressing α1GlyR, while at the same time utilizing the 
complex that could be formed between pyranine and cyclen 1 functionalized liposomes. When 
the interior of the liposome is filled with a fluorescent dye, such as Rhodamine B, then the 
fluorescence associated with this dye can be used as an indication of the presence of α1GlyRs. 
The fact that the fluorescence comes from a liposome encapsulating a solution of dye, and not 
one dye molecule that has been conjugated to the ligand is the key to generating up to a million-
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fold amplification of the signal, and thereby increased sensitivity in the visualization of cells 
expressing the receptor. 
 
2.4 Synthesis of HPTS-Ligand for α1GlyR 
 
 
A survey of the literature indicated that glycine binds to the receptor through the amino 
acid’s backbone. Therefore, we hypothesized that modifying glycine at either the COOH or NH2 
sites would compromise binding to the receptor due to the bulky nature of pyranine. We found 
that several other endogenous amino acids were capable of binding to GlyR with a reasonable 
affinity.
100,101
 These are shown in Figure 2.7. We selected homoserine as a potential precursor to 
form the HPTS-ligand conjugate because of it was similar to serine, which is known to bind, but 
has a longer side chain. This would allow a suitable distance between the two moieties to prevent 
any negative impact on the ability of the conjugate to bind to the receptor.  
 
 
Figure 2.7: Structures of known GlyR ligands. (Left) glycine, (middle) serine, and (right) 
alanine.  
 
Before synthesizing the HPTS-Hse conjugate, the binding of homoserine to GlyR was 
measured using the patch-clamp technique. HEK 293 cells designed to over-express a 
homonuclear variant of the receptor, α1GlyR, were obtained from Jensen and Kristiansen.102 
This variant was shown to behave in the same manner as wild-type GlyR. For each patch-clamp 
experiment, the plate of cultured cells were placed onto the stage and bathed in an extracellular 
solution (ECS) (140 mM NaCl, 3.5 mM KCl, 1.25 mM Na2HPO4, 2 mM MgCl2, 2 mM CaCl2, 
10 mM glucose, 10 mM HEPES, pH 7.35). Solutions of glycine and homoserine of 
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concentrations ranging from 1 to 100 uM were made in the same extracellular solution. The 
intracellular solution (ICS) (140 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM EGTA, 2 mM 
MgATP, 10 mM HEPES, pH 7.3) was used inside the pipet with the silver wire electrode. 
Figure 2.8 summarizes the findings of the patch-clamp study, which was conducted using the 
same conditions as reported in the initial characterization of this receptor.
102
 Glycine was found 
to have an EC50 of 90 uM, which is similar to values reported in the literature, and homoserine 
was found to have an EC50 of 190 uM. Since the aim of our study was to develop a model system 
for the amplification of fluorescent imaging, we concluded that homoserine was a suitable 
ligand.  
                
 
 
Figure 2.8: Patch-clamp measurements of L-homoserine affinity to α1GlyR. (Left) Structure of 
L-homoserine. (Right) Graph of current (uA) vs concentration of ligand (uM). The open circles 
with x’s represent cells that had no response to glycine. These were not included in the 
calculation of the EC50. 
 
Scheme 2.3A shows the complete synthesis of HPTS-Hse. The first two steps in the 
synthesis of HPTS-Hse was to protect the carboxylic acid and amine groups of the amino acid. 
Homoserine was suspended in methanol and TMSCl was added to form the Hse methyl ester 
HCl salt. This was used in the next step without further purification. Next, boc anhydride was 
used with triethylamine to form N-boc-Hse methyl ester. The alcohol functional group was 
replaced with Br using carbon tetrabromide and triphenylphosphine. The yield for this reaction 
C
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was low (15%) due to the formation of an exceptionally stable five-membered lactone that 
homoserine forms between the carboxylic acid and the hydroxyl of the side chain, seen in 
Scheme 2.3B. The next step was to conjugate this brominated variant of Hse with HPTS via an 
ether linkage, using CsCO3 to deprotonate the phenolic group of the dye, and the phase transfer 
catalyst TBAF. The reaction was heated to 45°C. This step resulted in a yield of 70%. Alkylation 
of HPTS causes a blue shift in the emission spectrum and we used this to monitor the reaction by 
fluorimetry. Finally, the protecting group was removed by TFA in DCM to give HPTS-Hse. The 
overall yield for this synthesis was 10.5%, with the major loss resulting from the formation of the 
lactone.  
A.  
 
B.  
 
Scheme 2.3: Synthesis of HPTS-Homoserine. (A) Synthesis of HPTS-Hse. (i) Formation of the 
methyl ester HCl salt using TMSCl in methanol. (ii) Boc-protection of the amino acid using boc 
anhydride and triethylamine in MeCN. (iii) Conversion of the alcohol side group to the alkyl 
bromide using CBr4 and Ph4P. Yield from i-iii was 15%. (iv) Alkylation of HPTS with the Br-
Hse intermediate using CsCO4, TBAF in acetone at 45°C. Yield for this step was 70%. (v) 
Deprotection of the amino acid using TFA in DCM. This reaction gave quantitative yield. The 
overall yield for i-v was 10%. (B) Depiction of the formation of the homoserine lactone. This 
product accounted for nearly 80% of the homoserine used in the boc-protection step. 
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This compound was titrated against the cyclen 1 receptor to show that conjugation to 
homoserine did not diminish binding, (Figure 2.9). HPTS in PBS (pH 7.0) has a λex = 405 nm 
and λem = 510 nm and HPTS-Hse in PBS (pH 7.0) has λex = 402 nm and λex = 427 nm. The 
titrations show a Ka of approximately 5 x 10
4
 M
-1
 and a loss of 60% of fluorescence.  
 
 
Figure 2.9: Fluorimetric titrations of HPTS-Hse with cyclen 1. Ka was found to be 5 x 10
4
 M
-1
. 
The inset shows the amount of fluorescence that is quenched from binding with cyclen. The dye 
was dissolved in phosphate saline buffer (10 mM sodium phosphate, 100 mM NaCl, pH 7.0) 
with stock solutions (100x) of cyclen in DMSO. Excitation was 402 nm with emission monitored 
at 427 nm. 
 
 
2.5 Synthesis of a Negative Control 
 
 
One of the aims of this project was to show that it is the interaction between the cyclen 
receptor and pyranine that results in associated fluorescence from the liposomes containing the 
reporter dye. To demonstrate that there is no nonspecific binding between the liposomes and the 
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cells expressing the GlyR, a control compound was synthesized (Figure 2.10B). We believed 
that homoserine conjugated to aniline would still bind to the GlyR but would not be bound by the 
cyclen receptor (Figure 2.10A). The brominated homoserine intermediate was reacted with 
aniline in water with SDS and NaHCO3 to give boc-Hse-OMe aniline. This was deprotected in 
the same manner that the HPTS-Hse was to give the final product with an overall yield of 30%. 
Initially, fluorimetric titrations were attempted to demonstrate lack of binding to the cyclen 
receptor, however the alkylated aniline fluoresced at such a low intensity that the results were 
inconclusive. Instead, isothermal titration calorimetry was used to measure the interactions 
between Hse-aniline and the cyclen receptor. Figure 2.11 shows the results from the ITC 
experiment, indicating that there is no significant binding of Hse-aniline to the cyclen receptor. 
Note the difference in the magnitude of the y axis when compared to that shown in Figure 2.4. 
 
 
Figure 2.10: Proposed negative control experiment using aniline-Hse. (A) General scheme 
showing the proposed control ligand binding to the target receptor. Subsequent addition of 
cyclen-liposomes would be unable to bind to the ligand, leading to a lack of associated 
fluorescence with the cells. (B) Synthesis of the control compound. (vi) NaHCO3 and SDS in 
water. (vii) The conjugate was deprotected using the same conditions as (v) in Scheme 2.2. 
Overall yield: 30%. 
 
A 
 
 
 
 
 
B 
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Figure 2.11: Isothermal titration calorimetry of aniline-Hse and cyclen 1. (A) Raw data for the 
titration of a 0.25 mM solution of aniline-Hse with a 5 mM solution of cyclen-Ome  in methanol. 
(B) Integrated data from (A), corrected by the heat of cyclen-Ome dilution, normalized to moles 
of injectant and plotted as a function of cyclen 1/aniline-Hse ratios.  
 
 
2.6 Synthesis of Liposomes 
 
 
The synthetic scheme for the modified cyclen receptor was previously developed by 
Kaushik et al, and is shown in Scheme 2.2.
67
 The cyclen receptor used in the following 
experiments consisted of the urea-based arms with the p-OMe-phenyl group terminating each 
arm (Ka = 9 x 10
6
 M
-1
). The cyclen core included the p-NO2-benzoyl group, which was reduced 
to the amine. This was used to make the liposomes containing the reporter dye, Rhodamine B. 
Liposomes were made with the cyclen-Ome 2 receptor in the following manner. The 
mixture of lipids which consisted of 98.5 mol% egg yolk L-α-phophatidylcholine (EYPC) and 
1.5 mol% cyclen receptor lipid were dissolved in 190 proof ethanol and dried under vacuum to 
form a thin film. The lipid film was hydrated using 2 mL of 50 nM Rhodamine B in phosphate 
A 
 
 
 
B 
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buffer solution (PBS) (10 mM sodium phosphate, 100 mM NaCl, pH 7.4). The solution was 
subjected to 5 freeze/thaw cycles (acetone/dry ice bath and water at room temperature). In order 
to achieve unilamellar vesicles of a consistent size, the solution was extruded through a 400 nm 
membrane 21 times. The liposomes were then purified using size-exclusion chromatography 
(Sephadex G-10 and the same PBS solution) to give a final volume of 1.7 mL of 400 nm cyclen 
functionalized liposomes encapsulating 50 nM Rhodamine B.  
 
2.7 Confocal Microscopy Study 
 
 
Cells studies were carried out using HEK-293 cells expressing the α1GlyR receptor.102 
Confocal microscopy was used to show HPTS-Hse binding to the receptors on the cell 
membranes and after addition of the liposomes to the medium, binding of cyclen to the HPTS 
conjugate quenched the green fluorescence and the red fluorescence of the liposomes replaced it. 
The results are shown in Figure 2.12. The following procedure was used. A culture of cells in 
ECS was grown on a poly-lysine cover slip. The cells were viewed in Brightfield mode first. 20 
uL of 5 mM HPTS-Hse was then added to the cells. Images were taken using Brightfield mode 
(A) followed by fluorescent mode (emission at 427 nm) (B). The two images were overlaid (C) 
to show that the green fluorescence was associated with the membranes of the cells. Next, 100 
uL of Rhodamine B-filled liposomes was added and brightfield (D) and fluorescent (E; emission 
at 627 nm) were taken. Both images are overlaid in (F). The liposomes are clearly visible in both 
images, however the fluorescent image makes it clear that liposomes have associated with the 
membranes of the cells, leading to a clear amplification of the fluorescence associated with these 
cells. This labeling is clear even without washing away the unbound liposomes from the 
surrounding solution.  
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Figure 2.12: Confocal Microscopy Experiments Showing Amplification of Targeted 
Fluorescence. (A) Brightfield image of cells after the addition of 20 uL of 5 mM HPTS-Hse. (B) 
Fluorescent mode image of the same cells. (C) Combined BF and FM images. (D) Brightfield 
image of cells and HPTS-Hse with the addition of 100 uL of liposomes containing Rhodamine B. 
(E) Fluorescent mode image of these same cells. (F) Combined BF and FM images. (G) Control 
experiment showing Aniline-Hse bound to α1GlyR. Combined BF and FM image. (H) Same 
cells after the addition of liposomes. (I) FM image of the lipsomes, which are seen to have no 
affinity to the cells. (ECS buffer: 137 mM NaCl, 5.4 mM KCl, 10 mM HEPES, 10 mM glucose, 
1 mM CaCl2, 1 mM MgCl2, pH 7.4) 
 
 
A new plate of cells was used for the control experiment. Panel G shows a group of cells 
after the addition of 20 uL of 5 mM Hse-aniline (emission at 433 nm). After the addition of 100 
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uL of liposomes, there is no visible interaction between the liposomes and the cells. It is 
important to note that for this set of experiments, the cells were not grown on a poly-lysine 
coverslip. Because of this, the liposomes were found to be floating in the solution (I) further 
indicating that without the presence of pyranine for the receptor to bind, the liposomes form no 
non-specific interactions with the cells. This suggests that the pyranine-cyclen receptor system is 
a successful tool for cell labeling assays. 
 The presence of the liposomes results in an amplification of up to 1 million times the 
intensity of the fluorescence associated with the glycine receptors that are labeled by single 
molecule probes. The addition of the aniline-Hse compound showed no specific interactions with 
the liposomes. 
 
2.8 Conclusions 
 
 
This work demonstrates the usefulness of the specific complex formed between the 
cyclen 1 receptor and pyrene dye derivatives as a tool to modify techniques that require some 
kind of specificity. In this case, the interaction was used to provide an amplification of the 
fluorescence used as a labeling and visualization method for cells expressing target receptors. 
Although glycine was used here only as a model ligand-receptor system, other useful therapeutic 
targets, such as cancerous cells could be visualized using this method, as long as a specific 
membrane receptor could be efficiently targeted. 
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Chapter 3 
 
 
Controlled Formation of Iminothiozolidinones and a Novel Nucleophile-Assisted 
Decyclization 
 
 
3.1 Heterocyclic-Forming Reactions of Thioureas 
 
 
In addition to the numerous applications of substituted thioureas, they also play an 
important role as precursors to the formation of heterocycles. The thioureas containing the 
ethanolamine arm, which we have used extensively, have been shown to form heterocycles in the 
presence of TsCl and NaOH (Scheme 3.1).
103-105
 This reaction tolerates the changes to the arm to 
include amines and thiol groups. This reaction is a pathway to the synthesis of 2-amino-aza-
heterocycles. These heterocycles are important in biology; chlonidine, a drug used to treat 
hypertension, is one example. Chlonidine analogs were synthesized using this scheme.
105
 
 
 
 
Scheme 3.1: Formation of 2-amino-aza-heterocycles from substituted thioureas.
105
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3.2 A Novel Synthesis of Iminothiozolidinones 
 
 
Following the successful completion of the cell labeling assay involving the HPTS-
cyclen 1 system, we planned to move forward with adapting this system to develop a 
methodology to selectively fuse liposomes. During this transition, we chose to revisit the 
synthesis of the cyclen receptor. The original reported synthesis involved building the arm onto 
the cyclen core in a stepwise fashion. While there were no inherent issues with this synthesis, it 
did involve the loss of some cyclen or cyclen-containing intermediate during each step. Cyclen, 
and especially p-NO2-bn-cyclen, is rather expensive, so we wanted to minimize any loss. 
Previous work by Kaushik et al had made adjustments to the synthesis to conserve cyclen for that 
reason. Shown in Scheme 3.2, the new synthesis involved the reactions to form the complete arm 
first. 4-Methoxyphenyl isocyanate was reacted with ethanolamine to form 4-methoxyphenyl urea 
ethanolamine. This was then reacted with bromoacetyl bromide in the presence of triethylamine. 
These steps afforded the full arm which was then ready to react with p-NO2-bn-cyclen. 
Following the reaction to conjugate the arm to the cyclen, the nitro group was reduced to the 
amine using Sn and HCl. Because of the ester bonds on the arms, the compound was dissolved in 
THF. HCl was generated by dripping sulfuric acid into a flask of NaCl. By controlling the 
conditions, this product was formed with fewer intermediates needing to be purified. The crude 
was dissolved in ethyl acetate and washed with ammonia water to give the final product. 
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Scheme 3.2 Modified synthesis of the cyclen 2 receptor. Note the use of the isocyanate rather 
than the isothiocyanate. a) ethyl acetate, rt, 1hr, 97%; b) bromoacetyl bromide, Et3N, DCM, rt, 5 
hrs, 90%; c) anhydrous DMF, Na2CO3, rt, 6 hrs, 62%; d) anhydrous THF, Sn/HCl(g), rt, 4hrs, 
63%. 
 
 
This synthesis was developed for the cyclen receptor variant that contained a urea group 
and terminated in 4-methoxyphenyl. We decided for this next project that we wanted to use the 
original cyclen 1 compound which consisted of the thiourea and naphthyl group. The first 
reaction between 1-naphthyl isothiocyanate and ethanolamine proceeded as expected. The 
second step, which was the reaction of the thiourea with bromoacetyl bromide, produced an 
unexpected product. After the first unexpected result, we speculated that the nitrogen of the 
thiourea group was possibly reacting with the acyl bromide instead of the alcohol as we had 
intended, so we reduced the amount of base from 2 mol eq to 1 and switched from DCM to THF. 
This second reaction also produced a product other than the desired ester (Scheme 3.3). The 
products from both of these reactions were isolated and MS (ESI) revealed that the two products 
p-NO2-bn-cyclen 
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were isomeric heterocycles. We decided to explore this discovery further, which will be the 
subject of this chapter. 
The first thing that we considered was the difference between urea and thiourea. In the 
disubstituted urea, the electronegative oxygen would withdraw electron density from the 
nitrogens, making them less nucleophilic. The alcohol of the side chain would then be the 
strongest nucleophile of the compound, and when added to bromoacetyl bromide, the ester forms 
as expected. Thiourea, on the other hand, contains a sulfur rather and oxygen. In this case, the 
nitrogens are now able to act as nucleophiles, and this matched our observations. There are then 
two nucleophilic nitrogen centers and bromoacetyl bromide has two electrophilic centers. Mass 
spectrometry confirmed that the products we obtained were the result of an initial attack by (we 
suspected) the nitrogen, followed by a second intramolecular attack to close the ring. Figure 3.1 
shows that the NMR spectra of the two products are significantly different, while mass 
spectrometry showed the products had the same masses.  
 
 
 
Scheme 3.3: Reaction of thiourea 1 forms two products. 
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Figure 3.1 
1
H NMR of isomeric heterocycles. product 1a is formed through the reaction at the 
alkyl-substituted nitrogen. 1b forms in a similar manner through reaction at the aryl-substituted 
nitrogen. Peaks labeled a are assigned to the methylene group on the ring, b and c are the ethanol 
arm methylene groups, and d is the hydroxyl H. 
 
The most significant aspect of this discovery was that we were able to switch which of 
the two isomers was the major product of the reaction by simply changing the amount of base 
and the solvent used. Furthermore, these reactions result in two products at most. Typically, 
when a compound with multiple nucleophilic centers is reacted with a compound with two 
electrophilic centers, a polymer mixture would be the expected result. These conditions are 
usually not synthetically useful. The crude NMR spectra of our reactions, however, indicate a 
simple mixture of two isomers with no other significant side products. We thought then that this 
reaction would be a useful route to the creation of a library of thiourea based heterocycles. 
 
 
 
 
33 
 
 
3.3 Structure Elucidation of Heterocyclic Isomers  
 
 
Our first goal was to determine the structure of the isomers we had synthesized from 
naphthyl thiourea ethanolamine. Figure 3.1 depicts the 
1
H NMR of the isomers, designated 1a 
(top) and 1b (bottom). Despite the similar structures, these two compounds have distinctly 
different spectra. The spectrum of 1a  is characterized by a singlet which can be attributed to the 
methylene that has been added to the thiourea from the haloacetyl halide. The equivalent group 
in 1b, however, appears as a pair of doublets that are downfield shifted in comparison. In 1a, the 
two methylene groups of the ethanol arm are found as two triplets in the vicinity of the singlet 
whereas in 1b these methylene groups are the most upfield shifted and appear to have higher 
order splitting patterns.  
The source of this dramatic difference in the two NMR spectra is a chiral center that is 
present in 1b. In this structure, the naphthalene ring is unable to rotate due to the carbonyl on the 
neighboring five-membered ring. The rigid conformation and position on the naphthalene group 
causes the methylene of the five-membered ring to behave like a diastereomeric group, each 
hydrogen being split by the other. The naphthalene ring of 1a, on the other hand, is an additional 
bond away from the equivalent methylene group, so it is unable to influence those hydrogens to 
the same extent.  While the NMR spectra provide a clear way to tell the two products apart, they 
did not provide any conclusive structural information when viewed alone.  
In order to better understand the structures, a series of 2D NMR experiments were run. 
First, the HSQC (Heteronuclear Single Quantum Correlation) experiment was run for each 
isomer, 1a and 1b. The heterocyclic products have three regional spin systems. The naphthalene 
group is isolated by the thiourea bond. There is a lone methylene group found on the heterocycle 
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that came from the bromoacetyl bromide and is further isolated by a carbonyl. Finally, the 
ethanol arm is on the far nitrogen of the thiourea. Additional structural information came from 
the subsequent HMBC (Heteronuclear Multiple Bond Correlation) experiment. 
 HMBC shows the association of one group to a group one or two bonds away. This leads 
to important connectivity information within a compound. At this point, we believed 1a to be a 
five-membered ring closed through the two nitrogens of the thiourea due to the disappearance of 
the NH peaks. The pair of doublets in 1b suggested a rigid structure, such as a six-membered 
ring, which could form if the ring closed through the alkyl nitrogen of the thiourea and the OH of 
the arm (Figure 3.2). HMBC spectra were taken in an effort to prove these hypothesized 
products (Figure 3.3 and 3.4). The HMBC of 1a showed correlation between the methylene 
groups of the ethanol arm, b and c, with each other but not with the methylene of the 
heterocycle, a. That methylene, a, however, showed cross peaks with C=N and C=O. This 
pattern would fit with a five-membered heterocycle. The HMBC of 1b shared a similar pattern of 
cross peaks, with a correlation between the heterocycle’s methylene and the arm group notably 
absent, suggesting that 1b was likely not a six-membered ring. The NMR experiments were not 
conclusive, however, which led us to attempt crystallization of the different compounds for 
single crystal x-ray crystallography. 
 
Figure 3.2: Possible heterocycles formed from the reaction of thiourea 1 and 
bromoacetyl bromide. 
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Figure 3.3: 2D NMR study of 1a. (A) HSQC of 1a. (B) HMBC of 1a. The black lines indicate 
correlations between hydrogen types and other carbons. The gray lines indicate the peaks that 
correlate the hydrogens to the same carbon. Note that these peaks appear spaced evenly on either 
side of the hydrogen peak. Green circles indicate correlations we expect to see and red circles 
indicate correlations that are expected to be absent. 
a 
b 
c 
A 
B 
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Figure 3.4: 2D NMR study of 1b. (A) HSQC of 1b. (B) HMBC of 1b. The black lines indicate 
correlations between hydrogen types and other carbons. The gray lines indicate the peaks that 
correlate the hydrogens to the same carbon. Note that these peaks appear spaced evenly on either 
side of the hydrogen peak.  
a 
c 
A 
B 
 
b 
 
 
  
 
 
37 
 
Three variants yielded successful crystal structures, which are shown in Figure 3.5.These 
crystal structures, obtained by Dr. Peter Zavalij of the University of Maryland, prove that the 
five-membered ring forms at the alkyl nitrogen and closes through the sulfur of the thiourea, 
resulting in an iminothiozolidinone. All products that followed this pattern, indicated by a singlet 
on NMR with upfield shifted aromatic peaks, were designated as “a” isomers.” We then 
hypothesized that the second isomer was the product of ring formation from the aromatic 
nitrogen with closure through the sulfur to also form an iminothiozolidinone. These isomers were 
designated as “b” isomers and could be identified by the pair of doublets or the downfield shifted 
aromatic peaks.  
It is important to note that the pair of doublets was seen in variants containing the 
naphthalene group but not the phenyl derivatives. The methylene group on the ring appears as 
two doublets in the naphthyl b rings because of the fixed orientation of the aryl group due to 
steric hindrance from the carbonyl, leading to a chiral C-N bond. This hindrance is absent in the 
a ring series. The p-phenyl thiourea cyclized products showed singlets for both the a and b 
isomers. This is because of the symmetrical nature of the ring. The phenyl derivatives were 
instead characterized by their aromatic peaks, which always appeared as two sets of doublets for 
each product.  
         
Figure 3.5 Crystal structures of various products. 8a (left), 5a (middle), and 1a (right). Nitrogens 
are shown in blue, oxygen in red and sulfur in yellow. Structures were solved by Dr. Peter 
Zavalij from the University of Maryland. 
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3.4 Library Formation 
 
 
After the initial discovery of the formation of two different heterocycles, we wanted to 
explore the versatility of this reaction and the possible products that could be formed. We began 
by building a library of thioureas to be used as precursors. Scheme 3.3 shows the general 
reaction between different isothiocyanates with various amines to form a thiourea. We used the 
naphthyl thiourea ethanolamine precursor as the base for variations. 
 
        
       
        
Scheme 3.4: Generalized scheme for the formation of thioureas and iminothiozolidinones. A 
shows the reaction to form thiourea. B shows the reaction to form the two isomers.  
  
 We first varied the aromatic group present while keeping the ethanolamine arm. We also 
made a variant with a butyl chain instead of an aromatic group. Next, we kept the use of naphthyl 
isothiocyanate constant and we varied the arm groups by introducing branching or lengthening 
the alkyl chain while keeping the alcohol function, or by removing the alcohol function by using 
a straight alkyl chain. A summary of these thioureas is shown in Figure 3.6. 
All of these products could be purified by recrystallization or aqueous work up with 0.1 
M HCl.. We later determined that the reaction went to completion after four hours at room 
A 
B 
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temperature and could be used without further purification (reactions monitored by NMR, not 
shown). 
 One of the reasons we chose to explore this set of reactions was the fact that we could 
control the reaction with base or solvent to favor one of the products over the other. For the 
isomer library synthesis, we decided to use the conditions that favored the b isomer formation. 
We did not want to limit the product formation to one isomer, and we felt that the b isomer 
would be the more biologically and synthetically interesting product of the two. All reactions 
were initially run in THF with 1 mol eq of Et3N at room temperature. Every thiourea formed the 
a  isomer in yields ranging from 28% to 78%. All thioureas also formed the b isomer except for 
4 (p-methoxyphenyl derivative). Of the ethanol arm derivatives, p-nitrophenyl thiourea formed a 
as the minor product (28%) and b as the major product (69%) at room temperature. The rest 
formed b as the minor product or in a similar yield to a. Interestingly, for the derivatives that 
used the propyl arm, b was the major product with only small amounts (~10%) of a produced. 
These structures are shown in Figure 3.7. 
After the initial reaction, two reactions were chosen for further optimization—those that 
used precursors 1 and 2. First, naphthyl thiourea ethanolamine was reacted with bromoacetyl 
bromide in DCM (with 2 eq of Et3N). These two changes results in a yield of 67% for the a 
isomer. When the same thiourea was reacted in THF, the b isomer was formed in 63% yield. 
These two reactions demonstrate that through a minor change to reaction conditions (solvent and 
relative amount of base), the major product can be switched to favor either isomer.  
We also compared the product distributions of the p-bromophenyl thiourea ethanolamine 
(2)  reactions at two different temperatures. The first reaction was at room temperature and the 
second was at -78°C. Both were in THF with 1 mol eq of Et3N. Figure 3.8 shows the results of 
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this temperature study. The difference in product ratios is clear, with the room temperature 
reaction giving 1:2 (b:a) and the -78°C reaction giving a 10:1 (b:a) distribution. In this case, the 
only change was in temperature, rather than solvent or base. These experiments prove the ability 
to tune the product formation through simple adjustments to reaction conditions which we 
believe lend a greater synthetic usefulness for this reaction pathway. 
 
 
 
Figure 3.6: Library of synthesized thioureas. 
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Figure 3.7. Library of iminothiozolidinone products formed from thiourea precursors. 
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Figure 3.8: 
1
H NMR study comparing the effects of temperature on ring formation. Top panel 
shows the 0°C crude reaction, where a nearly 1:1 (a:b) is observed. The additional peaks in the 
aromatic region can be attributed to left over starting thiourea as well as a small amount of the 
decyclization product. The bottom panel is the -78°C crude mixture.  
 
 
3.5 The Effects of Solvent and Temperature on Product Distribution 
 
 
 The discovery of 1a came about from an attempt to synthesize the full thiourea arm for 
the cyclen receptor. The reaction was run in DCM with Et3N (2 eq) with the belief that an ester 
would form. When this product was not seen, the reaction conditions were adjusted, leading to 
the formation of 1b. Following this realization, we wanted to explore the effects of solvent on the 
reaction. A series of reactions was conducted using the following conditions: 1 was dissolved in 
the chosen solvent and Et3N (1 eq) was added. Bromoacetyl bromide (1 eq) was added, and the 
reaction was stirred at room temperature for six hrs. The solvent was removed and the crude was 
dissolved in DCM and washed with sodium bicarbonate. The crude NMR of each reaction was 
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taken. The solvents chosen were acetone, acetonitrile, THF, ethyl acetate, DCM, and benzene. 
All solvents were aprotic and of varying polarities. All but DCM and benzene were capable of 
acting as hydrogen bond acceptors. Figure 3.9 shows that there is a distinct difference in the 
product distribution of isomers formed in the different solvents. Both isomers are present in all of 
the reactions, but acetonitrile and THF favor 1b considerably, acetone, ethyl acetate and DCM 
show some preference for 1b, and benzene shows a near equal formation of the two products. 
The integrations of relevant peaks and calculated product ratios are shown in Table 3.1. 
We hypothesized the hydrogen bonding capability with the alcohol arm was a driving 
force in the differences we observed. To test this, we ran the same series of reactions using the 
naphthyl propyl thiourea (11). The results of these experiments are shown in Figure 3.10 and 
Table 3.2. 11b is the major product in each reaction with close to a 90% b to 10% a yield seen in 
each reaction. This clearly demonstrates the importance of the auxiliary arm group in the 
formation of these iminothiozolidinones.   
 We next decided to explore the effect of the arm in controlling the reaction at different 
temperatures. As we noted before, the reaction of p-bromophenyl thiourea (2) at room 
temperature favored the formation of 2a while the reaction at -78°C favored 2b. We propose that 
intramolecular hydrogen bonding between the terminal alcohol and the alkyl nitrogen of the 
thiourea is able to form to a greater extent at the cold temperature. This hydrogen bond leads to 
the formation of a stable five-membered ring. The alkyl site is effectively blocked through this 
interaction, resulting in reaction at the aryl position. As the temperature is increased to 20°C, the 
solvent (THF) overcomes this complex to form an intermolecular bond. This frees the alkyl 
position, which we have observed to be the favored nucleophilic center in this thiourea.  
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Figure 3.9: Solvent effects on thiourea 1 reactions. 
1
H NMR taken for each reaction run in the 
solvent indicated. All other reaction conditions were kept the same. Peaks a and b are from the 
CH2 of the ring of isomer 1b, peak c is the CH2 on the ring of isomer 1a and peak d is the CH2 
closest to the nitrogen on the arm of 1a. 
 
Table 3.1: Comparison of isomers formed from the reaction of thiourea 1. 
Solvent Integration  
 a (CH) b (CH) c (CH2) d (CH2) Ratio (1b:1a) 
Acetone 1.00 0.97 0.55 0.56 4:1 
Acetonitrile 1.00 0.98 0.18 0.17 12:1 
THF 1.00 1.04 0.19 0.22 9:1 
Ethyl Acetate 1.00 0.97 0.71 0.76 3:1 
DCM 1.00 1.00 0.34 0.36 5.5:1 
Benzene 1.00 0.92 1.20 1.33 1.5:1 
The peak assignments are shown in the NMR (Fig. 3.7). Note that a and b both represent CH’s 
whereas c and d both represent CH2’s. The ratio of isomers was calculated using peaks a and d. 
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Figure 3.10: Solvent effects on thiourea 11 reactions. 
1
H NMR taken for each reaction run in the 
solvent indicated. All other reaction conditions were kept the same. Peaks a and b are from the 
CH2 of the ring of 11b, peak c is the CH2 on the ring of 11a and peak d is the CH2 closest to the 
nitrogen on the arm of 11a.  
 
Table 3.2: Comparison of isomers formed from the reaction of thiourea 2. 
Solvent Integration  
  a (CH)  b (CH) c (CH2) d (CH2) Ratio (11b:11a) 
Acetone 1.00 0.98 0.19 0.20 10:1 
Acetonitrile 1.00 1.00 0.15 0.17 12:1 
THF 1.00 1.07 0.28 0.29 7:1 
Ethyl Acetate 1.00 0.97 0.22 0.24 8:1 
DCM 1.00 0.99 0.12 0.14 14:1 
Benzene 1.00 0.96 0.24 0.26 8:1 
The peak assignments are shown in the NMR (Fig. 3.8). Note that a and b both represent CH’s 
whereas c and d both represent CH2’s. The ratio of isomers was calculated using peaks a and d. 
Based on the integrations and assuming the reaction went to completion, the average product 
distribution is 91% 11b and 9% 11a. 
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Bromophenyl propyl thiourea is not capable of forming this hydrogen bonded complex in either 
case, therefore we expected that the reaction of 10 at 20°C and -78°C would result in the same 
product ratio. This is indeed the result that we observed, shown in Figure 3.11. It is interesting to 
point out that 12b is the major product at either temperature with very little of 12a present.  
 
 
Figure 3.11: 
1
H NMR of the reaction of thiourea 10 at various temperatures. 
 
 
Following the exploration of the mechanism of the iminothiozolidinone reaction, we 
moved forward to demonstrate that these products were stable by subjecting them to reflux 
conditions. 1a was heated to 65°C in THF in the presence of HCl. The NMR (Figure 3.12) 
shows no change in the product, showing that this ring is stable and does not interconvert to 1b. 
When 1b was treated in the same manner, a change was observed. The product isolated from this 
reaction was not conversion to 1a but a new product entirely (Figure 3.13). 
10b 
10a 
10b 
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Figure 3.12: 
1
H NMR of the treatment of 1a with HCl. The ring was dissolved in acetonitrile 
and HCl was added to reach a pH of 3. The reaction was heated to 65°C for 24 hours. The NMR 
taken was of the crude reaction. ESI MS confirms lack of any product present. 
 
 
Figure 3.13: 
1
H NMR comparing 1b before and after refluxing with HCl.  Both NMRs were 
taken after purification of the products. The characteristic doublets, present before heating with 
HCl, disappear and a new singlet forms. There are also noticeable changes in the aromatic 
region. 
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3.6 Enthalpy vs Entropy Control of Product Formation 
 
 
In 1944, Woodward and Baer studied the difference in products formed in the Diels-
Alder reaction of maleic anhydride and 6,6-pentamethylenefulvene.
106
 They found that both the 
endo and exo products formed to different extents depending on the reaction conditions. Around 
the same time, Catchpole, Hughes and Ingold explored in depth the similar phenomenon in the 
nucleophilic substitution of allylic halides.
107
 While observations of differences in product 
distributions had been made by Meisenheimer et al as early as 1930
108
, it took a number of years 
for the concept of thermodynamic versus kinetic control of reactions to be established in main 
stream chemistry.
109
 Since then, the ability to control product formation by selecting conditions 
that favor the kinetic or thermodynamic product has been widely used in synthesis.
110
 In general, 
the kinetic product is the product that forms due to the pathway having a lower energy barrier, 
compared to the thermodynamic product, which may have a higher energy barrier but leads to a 
more stable product. Temperature and reaction time can be used to favor isolation of one product 
over the other. One of the requirements in this system is the ability of these two products to 
interconvert from a reversible step. 
 The lack of conversion between the two isomers means that there is no thermodynamic 
product in our system. Instead, the kinetic product is always formed. At -78°C, the reaction is 
under entropy control. This is due to the fact that an  intramolecular H-bond is able to effectively 
block the alkyl nitrogen through the formation of an exceptionally stable five-membered ring 
(Figure 3.14A) This results in a loss of entropy, but the formation of the ring at the aryl-N 
position, which is favored under these conditions, makes up for this loss. At higher temperatures, 
the reaction is under enthalpy control. At 20°C, the H-bonding between the OH of the arm and 
the solvent dominates, leaving both nitrogen positions exposed. The reaction takes place at the 
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alkyl-N, forming the a isomer and resulting in a greater release of energy than if the b isomer 
formed, due to the extension of the conjugated system (Figure 3.14B). When the thiourea with a 
propyl arm (10) is used instead, there is no formation of the H-bond at either temperature 
(Figure 3.14C), therefore we see the similar composition of products at both 20°C and -78°C 
(Figure 3.11).  
 
 
Figure 3.14: Depiction of temperature effects on the cyclization of functionalized p-
bromophenyl thioureas. (A) Thiourea 1 at 0°C, (B) the same thiourea at -78°C and (C) thiourea 
11 at either temperature. The arrow indicates the favored nucleophilic position. 
 
While it is common perception that nitrogens of aliphatic amines are more nucleophilic 
than those of anilines, it might not be necessarily true in the case of thiourea nitrogens. Whereas 
the aromatic amines exhibit lower nucleophilicity due to the delocalization of lone pair of 
nitrogen into the aromatic ring, both nitrogens in thiourea are already sp
2
 hybridized due to the 
resonance with thiocarbonyl moiety (Figure 3.15). We have found that cyclic voltammetry is a 
promising way to establish relative affinity of thioureas to an electron, which might serve as an 
estimate of relative nucleophilicity for the compounds with similar sterics (Figure 3.16).  
 
 
Figure 3.15: sp
2
 hybridization of aliphatic and aromatic nitrogens in thioureas due to the 
resonance delocalization of lone pairs. 
A                     B     C 
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Figure 3.16: Cyclic Voltammetric Study of Nucleophilicity of Various Thioureas. A. Cyclic 
voltammetric response on gold electrode of 1 mM THF solution of butyl ethanolamine thiourea 5 
(red line), naphthyl ethanolamine thiourea 1 (green line), naphthyl propylamine thiourea 11 (blue 
line), bromophenyl ethanolamine thiourea 2 (black line) and 0.1 M TBAPF6. Scan rate: 0.1V/s. 
B. Structures of compounds used in cyclic voltammetry. 
 
Four compounds used to validate the applicability of cyclic voltammetry to study of 
relative affinity of thiureas to electrons differ in the following way: an aliphatic thiourea 5 was 
supposed to have two nitrogens of similar nucleophilicity and was used as a reference 
compound. Two naphthyl thioureas 1 and 11 were different in the terminal group X: whereas 
thiourea 1 was triply nucleophilic due to the presence of an OH group, the thiourea 11 was 
terminated with an inert methyl group. Finally, bromophenyl thiourea 2 was different from 1 by 
the electron withdrawing nature of its aromatic moiety. The reduction and oxidation potentials 
for compounds 1, 5 and 11 were very similar (the reduction was observed at -0.5 V, and 
oxidation was observed at – 0.07 V), however the corresponding potential for compound 2 were 
quite different (-0.34 V for reduction and 0.11 V for oxidation). These observations suggest the 
following: 1) relative affinity of compounds 1, 5 and 11 to an electron was very similar; 
implying similar effects of alkyl and 1-naphthyl groups, as well as negligible influence of an OH 
auxiliary; 2) significantly higher affinity of compound 2 to an electron was observed, which is in 
line with its relative electron deficiency.  
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3.7 A Novel Nucleophile-Assisted Decyclization of Iminothiozolidinones 
 
 
 During the study of the effect of temperature as a means of control, we discovered an 
additional reaction taking place. 1b, when treated with a nucleophile under acidic conditions at 
reflux, underwent a decyclization that resulted in the conversion of iminothiozolidinone into 
aminooxoethylcarbamothionate. 2b also reacted in a similar fashion and the crystal structures of 
these two are shown in Figure 3.17. 
            
 
Figure. 3.17: Crystal structures of various decyclization products. 15 (left) and 16 (right) 
Nitrogens are shown in blue, oxygen in red, and sulfur in yellow. These structures were solved 
by Dr. Peter Zavalij of the University of Maryland. 
  
The decyclization was first observed when the crude reaction mixture of bromophenyl 
ethanolamine thiourea 2 formed at -78°C was heated to 65°C. The NMR shows a loss of the pair 
of doublets and the emergence of a singlet in their place. Additional changes to the aromatic 
peaks can be seen. This NMR was also different from that of 2a. MS (ESI) and crystal structures 
confirm that the following reaction took place: Substitution of the auxiliary alcohol by the 
nucleophile, bromine, triggered the decylization of the iminothiozolidinone. The intermolecular 
nucleophile, OH, attacks the electrophilic carbonyl center, leading to an opening of the ring and 
subsequent loss of the parent thiourea scaffold. This reaction requires an external nucleophile, in 
this case from the triethylammonium bromide formed during the previous step, as well as H
+
 
from an acidic medium. For reasons stated previously, there was only one equivalent of base 
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used, leading to an excess of acid in the final crude mixture. The proposed mechanism is shown 
in Scheme 3.5. Scheme 3.6 shows all of the decyclized products that have been synthesized in a 
similar manner. 
 
 
 
Scheme 3.5: Proposed termolecular mechanism for decyclization of iminothiozolidinones. Note 
that this mechanism involves a cascade of steps, with no intermediate being observed. 
 
 
 
 
  
Scheme 3.6: Formation of different decyclization products. The general reaction involved 
dissolving the ring in acetonitrile or THF and adding enough HBr or HCl to achieve a pH of 3. 
The reaction was heated to 65°C for 4-6 hrs. Products may also be formed by heating up the 
crude ring formation reaction in certain conditions. 
 
This reaction is an example of a termolecular mechanism. It is dependent on the external 
nucleophile as well as the internal nucleophile found on the arm.  We attempted to prove this 
through a control experiment using bromophenyl thiourea propylamine 11b. The crude reaction 
to form this compound was treated to the same reflux conditions with the addition of water and 
the reaction was monitored by NMR before and after reflux. Figure 3.14 shows that there was no 
significant change in the compound after reflux, illustrating the role of the pendant OH in the 
decyclization. This group must be present in the compound to undergo decyclization. The 
presence of an internal nucleophile is required so that the reaction relies one the attack of only 
the external nucleophile to begin. It is interesting that the series of b isomers will undergo this 
13 R = Naphthyl, X = Br, Z = H 
14 R = Naphthyl, X = Cl, Z = H 
15 R = Naphthyl, X = Br, Z = CH
3
 
16 R = p-Br-ph,   X = Br, Z = H 
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cyclization, but ethanolamine-based a isomers tested, no decyclization was observed by NMR 
(Figure 3.18) or MS.  
 
Figure 3.18: Reflux of 10b ring crude reaction. 
1
H NMR comparing the mixture before and after 
reflux in the presence of HBr. A small amount of water was added to show that the OH source 
must be intramolecular. The NMR indicates that no significant change took place, suggesting the 
ternary molecular mechanism takes place. This also shows lack of interconversion between the 
two isomers. 
 
The proposed mechanism is believed to be correct based on several observations. First, 
the –OH group must be present on the molecule, it cannot come from external conditions, as 
shown in Figure 3.18. Next, the reaction requires an acidic environment, which was proven when 
the same reaction was run using 3 equivalents of triethylamine instead of 1, resulting in no 
formation of the decyclized product. Finally, additional mechanisms were considered following 
some helpful discussions with Dr. Hartman. (Scheme 3.7), but ultimately it was the lack of a 
discernible intermediate that led to the final proposed mechanism. 
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Scheme 3.7. Alternative possible mechanism for the decyclization reaction. 
 The mechanism we have proposed could be drawn in a step-wise fashion, as shown in 
Scheme 3.8, however this too was not selected due to the formation of an intermediate. If this 
was the reaction pathway, the intermediate is the same for both a and b, which would mean both 
rings form the same product, or lead to the degradation of a. However, several experiments 
contradict this finding. The treatment of 1a with HCl and heat leads to no change in the ring, and 
if Scheme 3.8 was accurate, this reaction of 1a should have led to the formation of 14. An 
experiment in which a mixture of 2a and 2b were heated in the presence of HBr resulted in the 
loss of all of 2b to form the decyclized product, but none of 2a reacted. These observations, 
when taken together, led us to proposed the mechanism in Scheme 3.5.  
 
Scheme 3.8. Possible step-wise mechanism for the decyclization reaction. The reaction of b is 
shown in the top while the reaction of a is shown in the bottom. 
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3.8 Conclusions 
 
 The initial reaction of thiourea 1 to form the two different isomers was expanded to 
create a library of 20 different products using 11 thioureas. The products and yields from these 
reactions are summarized in Scheme 3.9.  
 
1 R = 1-Naphthyl 
R’ = CH2CH2OH 
1a R = 1-Naphthyl 
R’ = CH2CH2OH 
1b R = 1-Naphthyl 
R’ = CH2CH2OH 
67% / 20% 
26% / 63% 
2 R = 4-Bromophenyl 
R’ = CH2CH2OH 
2a R = 4-Bromophenyl 
R’ = CH2CH2OH 
2b R = 4-Bromophenyl 
R’ = CH2CH2OH 
14% / 65% 
3 R = 4-Nitrophenyl 
R’ = CH2CH2OH 
3a R = 4-Nitrophenyl 
R’ = CH2CH2OH 
3b R = 4-Nitrophenyl 
R’ = CH2CH2OH 
28% / 69% 
4 R = 4-Methoxyphenyl 
R’ = CH2CH2OH 
4a R = 4-Methoxyphenyl 
R’ = CH2CH2OH 
4b Not observed 60% 
5 R = n-Butyl 
R’ = CH2CH2OH 
5a R = n-Butyl 
R’ = CH2CH2OH 
5b Not observed 20% 
6 R = 1-Naphthyl 
R’ = CH(CH3)CH2OH 
6a R = 1-Naphthyl 
R’ = CH(CH3)CH2OH 
6b R = 1-Naphthyl 
R’ = CH(CH3)CH2OH 
27% / 17% 
7 R = 1-Naphthyl 
R’ = CH2CH(CH3)OH 
7a R = 1-Naphthyl 
R’ = CH2CH(CH3)OH 
7b R = 1-Naphthyl 
R’ = CH2CH(CH3)OH 
29% / 11% 
8 R = 1-Naphthyl 
R’ = CH2CH2CH2OH 
8a R = 1-Naphthyl 
R’ = CH2CH2CH2OH 
8b R = 1-Naphthyl 
R’ = CH2CH2CH2OH 
37% / 36% 
9 R = 1-Naphthyl 
R’ = 
CH2CH2CH2CH2OH 
9a R = 1-Naphthyl 
R’ = 
CH2CH2CH2CH2OH 
9b R = 1-Naphthyl 
R’ = 
CH2CH2CH2CH2OH 
28% / 19% 
10 R = 4-Bromophenyl 
R’ = CH2CH2CH3 
10a R = 4-Bromophenyl 
R’ = CH2CH2CH3 
10b R = 4-Bromophenyl 
R’ = CH2CH2CH3 
9% / 79% 
11 R = 1-Naphthyl 
R’ = CH2CH2CH3 
11a R = 1-Naphthyl 
R’ = CH2CH2CH3 
11b R = 1-Naphthyl 
R’ = CH2CH2CH3 
17% / 60% 
12 R = 4-Bromophenyl 
R’ = CH2CH2OH 
12a R = 4-Bromophenyl 
R’ = CH2CH2OH 
12b Not isolated 27% 
 
Scheme 3.9. Summary of functionalized thioureas and iminothiozolidinone derivatives. R’’ 
equals to H for all compounds, except 12a. For 12a R’’= CH3. Labels “nu” denote nucleophilic 
centers in thioureas, and labels “e” denote electrophilic centers in bromoacyl bromides. Note, 
that thioureas 1-9 and 12 have an additional nuclephilic OH group. The yields are reported as a% 
/ b% as isolated from a given reaction. These values were measured after column purification. 
Note that only the reaction of 1 was optimized for yield, and the two sets of yields provided 
come from two different reactions. 
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This work has expanded on the potential reactions of thioureas to form biologically 
relevant products. These reactions have no other side products, making purification 
straightforward after simple optimization of column conditions. In addition, a novel 
decyclization was discovered. The products of this decyclization were proven using x-ray 
crystallography and a potential mechanism was proposed based on experimental observations.  
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Chapter 4 
 
 
Future Work 
 
 
4.1. Experimental Support of a Termolecular Mechanism 
 
 
Reactions involving termolecular mechanisms are a rare class as they involve the 
collision between three different species. We were able to obtain crystal structures of two of the 
decyclization products, 15 and 16, providing irrefutable proof of the formation of these 
aminooxoethylcarbamothionates from the iminothiozolidinone b isomers. We were also able to 
demonstrate that the pendant OH is necessary for the decyclization, as well as an external 
nucleophile. Figure 4.1 further proves that the decyclization requires acidic protons to be 
present. These experiments have led us to suggest a plausible termolecular mechanism. 
We would like to conduct a kinetic study of this reaction to further support this proposed 
mechanism. Specifically, we would monitor the decyclization reaction by variable temperature 
NMR. A kinetic profile could be established by varying the concentrations of 
iminothiozolidinone, acid, and nucleophile in CD3CN. This this could be used to either support 
or disprove our proposed termolecular mechanism.  
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Figure 4.1: 
1
H NMR of the ring formation step followed by heating in the presence of excess 
base. The precursor was thiourea 2.  
 
 
4.2 One Pot Synthesis of Aminooxoethylcarbamothionates 
 
 
 We were able to show that this series of experiments are well-suited to a one-pot 
synthesis protocol. The reaction of isothiocyanate and the amine that have been added 1:1 will go 
to completion within four hrs at room temperature (monitored by NMR). This step can also be 
done in any of the solvents that are suitable for the next step. Next, triethylamine and 
bromoacetyl bromide can be added to the same pot, leading to the ring formation. This step can 
be done at room temperature or cold temperatures (-45°C when in acetonitrile) to control the 
product distribution and finishes within 6 hrs. Finally, this mixture need only be heated to 65°C 
for 4 hrs to promote the decylization of any b isomer formed in the previous step. Any a isomer 
formed would remain unchanged. Therefore, the formation of aminooxoethylcarbamotionates 
can be achieved in 14 hrs by simply controlling the temperature. There is no need to change the 
2b 
2a 
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solvent at any step, which is important for the conversion of traditional syntheses to continuous 
flow protocols which are common in large-scale industrial syntheses. Additionally, the crude 
NMRs taken show that the reaction results in a clean mixture of products with no additional side 
products to be removed. Aqueous work up will remove the triethylamine and salts while the 
aminooxoethylcarbamothionate has a sufficiently different polarity that separation from the 
iminothiozolidinone via chromatography is easily done. Figure 4.2 shows the results of this 
series.  
 
Figure 4.2: One-pot reaction series forming aminooxoethylcarbamothionate from 
isothiocyanate. 
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4.3 Potential HIV-1 Reverse Transcriptase Inhibitors 
 
 
 This reaction that we have discovered is, to the best of our knowledge, completely 
unprecedented. We observe a complete rearrangement of the inherited RNC(S)NR scaffold to the 
RNC(O)CH2SC(O)NR. This is a remarkable reaction that deserves to be explored in its entirety. 
In addition, the aminooxoethylcarbamothionates that are formed are known to be a privileged 
motif.
111
 in HIV-1 reverse transcriptase inhibitors.
112-116
 Thus the products of this decyclization 
are of biological interest as well. The major advantage to formation of these products using our 
method is the quick, inexpensive synthesis that allows for multiple points of variation. We have 
already established a protocol to synthesize these products from fairly cheap, commercially 
available starting materials that could be easily adapted to an automated system for large scale 
production.  
 
 
 
Figure 4.3: Comparison of 16 to a known class of HIV reverse transcriptase inhibitors. (A) The 
crystal structure of 16 has been redrawn for comparison. (B) The general structure of the 
aminooxoethylcarbamothionates formed in the newly reported decyclization of 
iminothiozolidinones. (C) General structure of compounds known to be HIV-1 RTIs. 
 
 Our next goal would be to continue to expand the class of products that can be 
synthesized in this manner. To date, we have only considered bromoacetyl bromide or 1-
bromopropionyl bromide. We would like to explore the use of other capping agents as a means 
to synthesize other heterocycles. Figure 4.4 shows some possible cyclization products that could 
be formed using the same thioureas with different capping agents. We expect that we can achieve 
A.                           B.            C. 
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a similar control over the reaction through solvent and temperature due to the presence of the 
same auxiliary OH. We have somewhat explored the auxiliary chain length but we would like to 
find the limit at which we can exert control over the reaction in this manner. We can synthesize 
thioureas that terminate in amines instead of alcohols, but we have not explored their effect on 
the ring formation reaction. We would also like to expand the external nucleophiles that can 
participate in the decyclization step. The hydrohalogen acids are the most successful, however 
we have also seen promising results with 2-mercaptoethanol and amines. This would provide 
another avenue for diversity in the potential HIV transcriptase inhibitors. 
 
 
Figure 4.4: Potential reactions of N,N’-disubstituted thioureas with other capping agents. Each 
capping agent is doubly electrophilic. These reactions could make synthesis of other heterocycles 
more accessible. 
 
 Although we have identified the importance of base in the ring formation, we have not 
yet explored this in depth. We would like to explore the effect of base in combination with 
different solvents in the future in an attempt to push the reaction towards 100% formation of the 
a isomers. We are currently working on the synthesis of a third isomer using the naphthyl 
thiourea ethanolamine precursor.  In an effort to synthesize this compound, we have proposed a 
different synthetic route. We will form naphthyl thiourea morpholinone through the reaction of 
naphthyl isothiocyanate and morpholin-3-one with NaH in THF. Crude NMRs suggest the 
 
 
62 
 
formation of this product, however purification and characterization are still necessary. The 
structure of this isomer would be characterized by HSQC and HMBC. 
 
4.4 Cyclic Voltammetry as a Means to Assess Relative Nucleophilicity 
 
 
A protocol for assessment of relative nucleophilicity of two nitrogens in asymmetric 
thioureas will be developed. Chapter 3 included a cyclic voltammogram used to compare the 
redox potentials of selected thioureas in an effort to explain the differences in product 
distributions formed from various reactions with these precursors. Similar studies will be carried 
out on the number of thioureas that are subject to cyclization under conditions mimicking the 
reaction conditions, including a variety of solvents and temperature variations that allowed us to 
control the outcome of syntheses. Through a series of cyclic voltammetry experiment, we expect 
to find a relationship between relative reactivity of individual thioureas and the conditions of 
reactions.  
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Appendix A. 
 
 
Experimental Information for Chapter 2 
 
 
General 
L-Homoserine was purchased from TCI Chemicals and EYPC was purchased from Avanti Polar 
Lipids. All other chemicals were purchased from Sigma, Fisher, or Acros. Reactions were 
monitored by thin layer chromatography using silica gel plates with F254 indicator. Plates were 
visualized using UV and I2. Products were purified by silica gel column chromatography (silica 
gel 60, particle size 0.04mm-0.063mm) or size exclusion chromatography (Sephadex G-10 
purchased from Sigma). NMR spectra were taken on a Varian Mercury instrument operating at 
299.865 MHz or an Agilent 400 MHz NMR operating at 400.130 MHz. Chemical shifts were 
reported in ppm relative to the residual solvent peak. The 
13
C NMR spectra were taken on the 
same instruments at 75.408 MHz and 100.613 respectively. All NMRs were taken in DMSO-d6. 
Mass spectra were recorded on a Micromass Q-TOF 2 instrument (Manchester, UK) or a LCMS-
IT-TOF (Shimadzu Corporation, Columbia, MD) using the electrospray technique (positive 
mode). All spectrophotometric experiments were carried out on a Fluoromax 3 (Jobin-
Yvon/Horriba) spectrophotometer. Microcalorimic titrations were performed using a VP-ITC 
microcalorimeter (MicroCal, LLC, Northampton, MA) and analyzed using Origin-7 software.  
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Methyl homoserinate hydrochloride (i) 
L-Homoserine (0.536 g, 4.50 mmol) was suspended in methanol (21.5 mL) under inert 
atmosphere. The suspension was cooled to 0⁰C. Trimethylsilyl chloride (0.125 mL, 9.90 mmol) 
was added dropwise via syringe. The reaction was stirred for 22 hours at 20⁰C. The solvent was 
removed using a high vacuum rotary evaporator to give the product in quantitative yield. This 
compound has been previously synthesized. 
1
H NMR (300 MHz, DMSO-d6) δ 8.45 (br s, 2H), 
4.45 (t, J = 9.5 Hz, 1H), 4.41 – 4.18 (m, 2H), 4.07 (br s, 1H), 3.74 (s, 3H), 2.58 (m, 1H), 2.43 – 
2.16 (m, 1H). 
 
Methyl (tert-butoxycarbonyl)homoserinate (ii) 
Methyl homoserinate hydrochloride (i) (0.743 g, 4.38 mmol) was suspended in anhydrous 
acetonitrile (15 mL) at 20⁰C. Boc anhydride (1.05 g, 4.95 mmol) was added to the suspension. 
Triethylamine (1.22 mL, 9.0 mmol) was added slowly via syringe and the reaction was stirred for 
16 hours. Methylene chloride (60 mL) was added to the reaction. The organic layer was washed 
with distilled water, followed by 1 N HCl, saturated sodium bicarbonate and brine. The organic 
layer was dried over anhydrous sodium sulfate and then evaporated to give a white solid 
containing the desired product as well as the lactone by product. This was used in the next step 
without further purification. This compound had been previously synthesized. 
1
H NMR (300 
MHz, CDCl3) δ ppm 1.45 (s, 9H), 2.23-2.30 (m, 1H), 2.63-2.72 (m, 1H), 3.75 (s, 3H), 4.21-4.30 
(m. 2H), 4.40 (br s, 1H), 4.43 (t, J=3 Hz, 1H), 5.59 (br s, 1H). 
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Methyl 4-bromo-2-((tert-butoxycarbonyl)amino)butanoate (iii) 
The N-boc-Hse-OMe and lactone by product from (ii) was dissolved in anhydrous methylene 
chloride (20 mL) and cooled to 0⁰C. Carbon tetrabromide (1.052 g, 4.95 mmol) and 
triphenylphosphine (0.832 g, 4.95 mmol) were added to the solution in that order. The reaction 
was allowed to come to room temperature and stir for a total of 90 minutes. The solvent was 
removed by rotary evaporation to give an orange solid. This was dissolved in ethyl acetate and 
then filtered. The filtrate was collected and evaporated. The solid was then dissolved in a 
minimal amount of ethyl acetate and hexanes (3:7). The filtrate was added to a silica gel column. 
The final product was eluted with the same ethyl acetate and hexanes mixture. The overall yield 
for these three steps was 15%. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.44 (s, 9H), 2.15-2.27 (m, 
1H), 2.34-2.47 (m, 1H), 3.43 (t, J=2 Hz, 2H), 3.76 (s, 3H), 4.41 (t, J=3 Hz, 1 H), 5.13 (br s, 1H); 
13
C NMR (75 MHz, CDCl3) δ 192.67, 149.09, 107.87, 77.70, 77.27, 76.84, 71.16, 67.86, 67.64, 
52.83, 36.06, 29.71, 28.49, 24.03, 0.21. ESI MS m/z 296.07 and 298.07 (M+H)
+
 found, 
calculated for C10H19BrNO4, 296.04. 
 
Sodium 8-(3-((tert-butoxycarbonyl)amino)-4-methoxy-4-oxobutoxy)-3a1,9-dihydropyrene-
1,3,6-trisulfonate (iv) 
HPTS (0.048 g, 0.101 mmol) and cesium carbonate (0.132 g, 0.404 mmol) were suspended in 
anhydrous acetone (6 mL; pH 8). Tetrabutylammonium fluoride (150 uL) was added until all 
HPTS was in solution. N-boc-Br-Homoserine methyl ester (0.030 g, 0.101 mmol) was added to 
the solution. The reaction was stirred for 20 hours at 45⁰C. During the course of the reaction, the 
solution turned orange and some of the unreacted HPTS dropped out of solution. The unreacted 
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HPTS was removed via filtration and the filtrate was collected and the solvent removed on a 
rotary evaporator. The product was purified on a silica gel column, using methanol/chloroform 
(1:5) to elute. Once the product started coming off the column, the solvent was gradually 
increased to 35% methanol/65% chloroform. After collecting and drying the product, the HPTS-
boc-Hse-TBAF conjugate was dissolved in 5 mL acetone and 20 equivalents of NaI (0.250 g) 
was added. The solution was stirred overnight to remove the TBAF. The HPTS-boc-HSE 
conjugate precipitated out of the acetone and was collected via centrifugation. Yield: 0.052 g, 
70% 
1
H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9H), 2.24-2.35 (m, 1H), 2.39-2.50 (m, 1H), 
3.64 (s, 3H), 4.40-4.49 (m, 3H), 7.56 (br s, 1H), 8.18 (s, 1H), 8.34 (d, J=3 Hz, 1 H), 8.92 (d, J=1 
Hz, 1H), 9.01 (d, J= 4 Hz, 1H), 9.10 (d, J=2 Hz, 1H), 9.16 (s, 1H). 
13
C NMR (75 MHz, DMSO) 
δ 220.04, 207.31, 156.26, 143.82, 141.25, 140.35, 140.13, 128.70, 128.32, 126.98, 126.57, 
126.08, 125.77, 125.10, 121.18, 79.07, 52.61, 49.27, 40.97, 40.69, 40.41, 40.13, 39.86, 39.58, 
39.30, 31.40, 28.83. ESI MS m/z 185.15 (M+H)
4+
 found, calculated for C26H26NNa3O14S3 
741.02. 
 
Sodium 8-(3-amino-3-carboxypropoxy)-3a1,9-dihydropyrene-1,3,6-trisulfonate (v) 
To remove the boc protecting group, HPTS-boc-Hse was stirred in TFA and DCM (1:1) for 3 
hours. The TFA was then removed via rotary evaporator. The HPTS-Hse TFA salt was then 
dissolved in deionized water and sodium bicarbonate was used to adjust the pH from 1 to 7. The 
salts were removed by running the crude on a Sephadex column, eluting with diH2O. 
1
H NMR 
(300 MHz, DMSO-D6) δ ppm 2.09-2.19 (m, 1H), 2.29-2.39 (m, 1H), 3.64 (s, 3H), 3.72 (t, J=2 
Hz, 1H), 4.42-4.47 (m, 2H), 8.16 (s, 1H), 8.32 (d, J=3 Hz, 1H), 8.92 (d, J=3 Hz, 1H), 9.00 (d, 
J=2 Hz, 1H), 9.05 (d, J=3 Hz, 1H), 9.14 (s, 1H). 
13
C NMR (300 MHz, DMSO-D6) δ ppm 38.95, 
 
 
77 
 
49.16, 50.53, 60.38, 121.35, 121.60, 121.72, 124.19, 125.77, 127.14, 128.42, 128.86, 137.85, 
139.90, 143.60, 151.75, 171.76. . ESI MS m/z 161.05 (M+H)
4+
. Calculated for C20H16NNa3O12S3 
626.95 
 
Methyl 2-((tert-butoxycarbonyl)amino)-4-(phenylamino)butanoate (vi) 
Aniline (2.50 mmol), sodium bicarbonate (3 mmol), and sodium dodecyl sulfate (10 mg) were 
dissolved in deionized water (10mL) and heated to 45⁰C for ten minutes. Then N-boc-Br-
Homoserine methyl ester (3 mmol) was added to the reaction. The reaction was run at 45⁰C for 
48 hours and then the solvent was removed by rotary evaporation. The product was purified on a 
silica gel column using 1:9 Ethyl acetate/hexanes. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.46 (s, 
9H), 1.81-1.93 (m, 1H), 2.11-2.22 (m, 1H), 3.17-3.32 (m, 2H), 3.70 (s, 3H), 4.42 (t, J=5 Hz, 1H), 
5.20 (br s, 1H), 6.59 (d, J=3 Hz, 2H), 6.70 (t, J=3 Hz, 1H), 7.17 (t, J=2 Hz, 2 H), 7.26 (br s, 1H). 
13C NMR (75 MHz, DMSO) δ 171.76, 170.57, 159.91, 159.41, 158.91, 158.41, 151.75, 143.60, 
140.13, 139.95, 139.90, 137.85, 128.86, 128.42, 127.14, 125.77, 124.19, 121.72, 117.88, 114.05, 
110.21, 86.51, 79.79, 60.38, 53.58, 50.53, 49.16, 40.76, 40.48, 40.38, 40.21, 39.93, 39.65, 39.37, 
39.09, 38.95, 31.19, 30.42. ESI MS m/z 309.20 (M+H)
+
 found, calculated for  C16H25N2O4 
309.17. 
 
2-amino-4-(phenylamino)butanoic acid (vii) 
The protecting group was removed using the same procure as in (v). Instead of a column, the 
product was extracted into ethyl acetate and the solvent removed. Overall Yield: 30% 
1
H NMR 
(600 MHz, CDCl3) δ ppm 1.89-1.94 (m, 1H) 2.07-2.12 (m, 1H), 3.18 (br s, 3H), 3.28-3.37 (m, 
2H), 3.60-3.70 (m, 1H), 3.71 (s, 3H), 6.62 (d, j=2 Hz, 2H), 6.72 (d, j=1 Hz, 1H), 7.19 (t, j=2 Hz, 
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2H). 
13
C NMR (75 MHz, CDCl3) δ 173.38, 147.93, 129.48, 117.66, 113.08, 80.37, 77.64, 77.42, 
77.22, 76.80, 52.59, 51.71, 41.24, 40.04, 36.14, 32.57, 29.90, 28.52, 28.50, 28.42, 27.97, 1.22, 
0.20. ESI MS (DI, MeOH) m/z 209.22 (M+H)
+
 found, calculated for C11H16N2O2 208.12. 
 
Synthesis of cyclen 2 lipid 
Prepared as directed.
67
 
 
Preparation of Liposomes 
Egg yolk L-α-phosphatidylcholine and cyclen 2 lipid were combined in ethanol to make a 98.5% 
EYPC/1.5% cyclen 2 lipid mixture. The solvent was removed on a high vacuum to make a thin 
lipid film. This lipid film was hydrated in 2 mL PBS (10 mM sodium phosphate, 100 mM NaCl, 
pH 7.4) containing 50 nM Rhodamine B. During hydration the mixture was subjected to 5 
freeze- thaw cycles (dry ice/acetone bath, room temperature water bath). The resulting 
suspension was subjected to 21 high pressure extrusions through a 0.4 uM polycarbonate 
membrane to afford liposomes. These were purified via size exclusion chromatography using 
Sephadex G-10 and PBS minus Rhodamine B as the eluant. The liposomes eluted over 1.7 mL.  
 
Patchclamp Recordings 
α1GlyR-HEK293 cells (generously provided by Jensen102) were bathed in the extracellular 
recording solution (ECS). The cells were constantly perfused with the ECS using a gravity fed 
perfusion system. Micropipettes of approx. 2-3 MΩ resistance were used to patch each individual 
cell. The micropippettes contained a silver wire electrode and inctracellular solution (ICS). 
Voltage clamp readings were taken in the whole cell configuration using the range of 
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concentrations tested. Glycine and homoserine solutions were prepared in distilled water at 100x 
the concentrations needed and diluted with ECS. The concentration-response relationship was 
modeled using the Hill equation I = Imax/ (1 + (EC50/[drug])
n
) where I is the current induced by 
the drug at that concentration, Imax is the maximum current the drug can induce, EC50 is the 
concentration that gives half of the maximal current and n is the Hill coefficient
102
. 
 
 
Isothermal Titration Calorimetry 
0.25 mM aniline-Hse and 5 mM cyclen-OMe receptor was prepared in MeOH.  The solution of 
cyclen-OMe was in the syringe and injected into the cell containing the aniline-Hse solution. The 
reference cell contained pure methanol. Injections were 7 uL. There were a total of 35 with 300 s 
between each injection. The temperature was set to 25C. Data was corrected using a dilution 
experiment in which the same cyclen-OMe solution was titrated into a cell of pure MeOH. 
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Appendix B. 
 
 
Experimental Information for Chapter 3 
 
 
General Information: 
All chemicals were purchased from Sigma, Aldrich, Fisher, or Acros. Reactions were monitored 
by thin layer chromatography using silica gel plates with F254 indicator (200 uM from Dynamic 
Adsorbents). The formation of imidithiozolidinones using N-alkoxy-thioureas was monitored by 
eluting plates in 5:95 MeOH:DCM. The N-alkyl-thiourea reactions were monitored by eluting 
plates in 1:99 EtOAc:DCM. Plates were visualized using UV and I2. Products were purified by 
silica gel column chromatography (silica gel 60, particle size 0.04mm-0.063mm). NMR spectra 
were taken on a Varian Mercury instrument operating at 299.865 MHz or an Agilent 400 MHz 
NMR operating at 400.130 MHz. Chemical shifts were reported in ppm relative to the residual 
solvent peak. The 
13
C NMR spectra were taken on the same instruments at 75.408 MHz and 
100.613 respectively. All NMRs were taken in DMSO-d6. Mass spectra were recorded on a 
ThermoFisher Scientific LTQ Orbitrap Velos using the electrospray technique (positive mode).  
 
 
1-(2-hydroxyethyl)-3-(naphthalen-1-yl)thiourea  (1)  
1-naphthyl isothiocyanate (0.250 g, 1.35 mmol) was dissolved in ethyl acetate (10 mL). 
Ethanolamine (0.0815 mL, 1.35 mmol) was added and the reaction was stirred at room 
temperature for 1 hr. The solvent was removed in vacuo. The crude solid was recrystallized in 
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toluene to give 1 as a white powder (0.293 g, 88 %). This compound was previously 
characterized.
64
 
 
3-(2-hydroxyethyl)-2-(naphthalen-1-ylimino)thiazolidin-4-one (1a) 
1 (0.106 g, 0.43 mmol) was dissolved in dichloromethane (10 mL) and triethylamine (0.120 mL, 
0.86 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
(0.0477 mL, 0.516 mmol) in dichloromethane (1 mL) was added dropwise within five minutes. 
This reaction was stirred at room temperature for 8 hr. The crude was washed once with water 
(15 mL) and once with brine (15 mL) and then was concentrated under reduced pressure. The 
crude oil was purified using column chromatography (silica gel, MeOH/DCM 1:99) to give 1a as 
an orange oil (.0818 g, 67 %) 
1
H NMR (300 MHz, DMSO-d6) δ 7.92 (d, J = 9.1 Hz, 2H), 7.78 – 
7.64 (m, 1H), 7.64 – 7.32 (m, 3H), 7.16 – 6.91 (m, 1H), 4.99 (t, J = 6.0 Hz, 1H), 4.02 (s, 2H), 
3.97 (t, J = 6.2 Hz, 2H), 3.76 (q, J = 6.1 Hz, 2H); 
13C NMR (75 MHz, dmso) δ 172.15, 156.14, 
144.56, 133.93, 127.89, 126.87, 126.45, 125.96, 125.70, 124.14, 123.22, 115.16, 57.23, 44.90, 
32.60.  MS (ESI) ([M+H]
+
): found 287.08, calculated for C15H15N2O2S 287.08. 
 
2-((2-hydroxyethyl)imino)-3-(naphthalen-1-yl)thiazolidin-4-one (1b) 
1 (0.142 g, 0.576 mmol) was dissolved in anhydrous THF (6 mL) and triethylamine (0.0583 mL, 
0.576 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
(0.0533 mL, 0.576 mmol) in THF (1 mL) was added dropwise within 5 minutes. The reaction 
was stirred at room temperature for 11 hr. The precipitate that formed was collected by vacuum 
filtration. The solid was rinsed with THF followed by DCM. This solid, crude 1b, was suspended 
in DCM (10 mL) and triethylamine (0.0583 mL, 0.576 mmol) was added to neutralize the HBr 
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that had formed. This was then washed 2x with water (15 mL) and once with brine (15 mL). The 
organic layer was then dried over MgSO4 and the solvent removed in vacuo to give 1b as a pale 
yellow oil (0.103 g, 63 %). The filtrate from the reaction was concentrated under reduced 
pressure to yield crude 1a, which was purified using the same column conditions as above to 
give 0.0429g (26 %). 1b was characterized as follows: 
1
H NMR (400 MHz, DMSO-d6) δ 8.04 (d, 
J = 8.4 Hz, 2H), 7.77 – 7.39 (m, 6H), 4.53 (s, 1H), 4.48 – 4.19 (m, 2H), 3.33 (d, J = 5.8 Hz, 2H), 
3.30 – 3.14 (m, 2H); 13C NMR (101 MHz, DMSO) δ 170.67, 152.61, 132.70, 131.35, 128.38, 
127.92, 127.12, 126.16, 125.77, 125.21, 124.59, 121.36, 59.43, 53.29, 31.52. MS (ESI) 
([M+H]
+
): found 287.08, calculated for C15H15N2O2S 287.08. 
 
1-(4-bromophenyl)-3-(2-hydroxyethyl)thiourea (2) 
4-Bromophenyl isothiocyanate (0.250 g, 1.17 mmol) was dissolved in ethyl acetate (10 mL). 
Ethanolamine (0.0705 mL, 1.17 mmol) was added and the reaction was stirred at room 
temperature for 11 hr. The solvent was removed in vacuo. The crude solid was recrystallized in 
toluene to give 4a as a white powder (0.284 g, 88 %). 
1
H NMR (300 MHz, DMSO-d6) δ 9.67 (s, 
1H), 7.82 (s, 1H), 7.46 (m, 4H), 4.82 (s, 1H), 3.54 (m, 4H); 
13C NMR (75 MHz, dmso) δ 180.43, 
138.94, 131.24, 124.61, 115.69, 59.16, 46.43. MS (ESI) ([M+H]
+
): found 274.98 and 276.98, 
calculated for C9H12BrN2OS 274.98. 
 
2-((4-bromophenyl)imino)-3-(2-hydroxyethyl)thiazolidin-4-one (2a) 
2 (0.100 g, 0.363 mmol) was dissolved in anhydrous THF (5 mL) and triethylamine (0.0506 mL, 
0.363 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
(0.0336 mL, 0.363 mmol) in THF (1 mL) was added dropwise within 5 minutes. The reaction 
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was stirred at room temperature for 8 hr. The reaction mixture was vacuum filtered to remove the 
precipitate. The filtrate was concentrated in vacuo and then redissolved in DCM (10 mL). The 
crude was washed once with water (15 mL) and once with brine (15 mL) and then dried over 
MgSO4. The solvent was removed to give 2a as an orange oil (0.0404 g, 78 %). 
1
H NMR (300 
MHz, DMSO-d6) δ 7.54 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 2H), 4.85 (s, 1H), 4.03 (s, 2H), 
3.79 (t, J = 6.3 Hz, 2H), 3.61 (t, J = 5.9 Hz, 2H); 
13C NMR (75 MHz, dmso) δ 168.99, 153.19, 
144.50, 129.17, 120.25, 113.42, 53.91, 41.68, 29.68. MS (ESI) ([M+H]
+
): found 314.98 and 
316.98, calculated for C11H12BrN2O2S 314.98. 
 
3-(4-bromophenyl)-2-((2-hydroxyethyl)imino)thiazolidin-4-one (2b) 
2 (0.100 g, 0.363 mmol) was dissolved in anhydrous THF (5 mL) and triethylamine (0.0506 mL, 
0.363 mmol) was added. The mixture was cooled to -78°C using an acetone/dry ice bath. It was 
stirred for 10 minutes and then bromoacetyl bromide (0.0336 mL, 0.363 mmol) in THF (1 mL) 
was added dropwise within 5 minutes. After the reaction was stirred at -78°C for 6.5 hr, it was 
allowed to come up to room temperature. The precipitate that formed was collected by vacuum 
filtration. The solid was rinsed with THF followed by DCM. This solid, crude 2b, was suspended 
in DCM (10 mL) and triethylamine (0.0506 mL, 0.363 mmol) was added to neutralize the HBr 
that had formed. This was then washed 2x with water (15 mL) and once with brine (15 mL). The 
organic layer was then dried over MgSO4 and the solvent removed in vacuo to give 2b as a pale 
orange oil (0.0741 g, 65 %). 
1
H NMR (400 MHz, DMSO-d6) δ 7.66 (d, J = 8.8 Hz, 2H), 7.26 (d, 
J = 8.7 Hz, 2H), 4.59 (s, 1H), 3.45 (q, J = 6.0 Hz, 2H), 3.24 (t, J = 6.2 Hz, 2H);
 13
C NMR (101 
MHz, DMSO) δ 171.78, 153.87, 135.29, 132.28, 131.16, 121.69, 61.18, 54.92, 33.00. MS (ESI) 
([M+H]
+
): found 314.98 and 316.98, calculated for C11H12BrN2O2S 314.98. 
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1-(2-hydroxyethyl)-3-(4-nitrophenyl)thiourea (3) 
4-nitrophenyl isothiocyanate (0.250 g, 1.39 mmol) was dissolved in ethyl acetate (10 mL). 
Ethanolamine (0.0837 mL, 1.39 mmol) was added and the reaction was stirred at room 
temperature for 11 hr. The solvent was removed in vacuo. The crude solid was recrystallized in 
toluene to give 3 as a pale yellow powder (0.280 g, 83 %). 
1
H NMR (400 MHz, DMSO-d6) δ 
10.23 (s, 1H), 8.24 (s, 1H), 8.17 (d, J = 9.3 Hz, 2H), 7.88 (d, J = 9.2 Hz, 2H), 4.89 (s, 1H), 3.57 
(s, 4H); 
13C NMR (101 MHz, DMSO) δ 180.51, 146.89, 142.22, 124.96, 120.67, 59.29, 46.97. 
MS (ESI) ([M+H]
+
): found 242.06, calculated for  C9H12N3O3S 242.05.  
 
3-(2-hydroxyethyl)-2-((4-nitrophenyl)imino)thiazolidin-4-one  (3a)  
3 (0.20 g, 0.83 mmol) was dissolved in anhydrous THF (8 mL) and triethylamine (0.116 mL, 
0.83 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
(0.0766 mL, 0.83 mmol) in THF (1 mL) was added dropwise within 5 minutes. The reaction was 
stirred at room temperature for 8 hr. The reaction mixture was vacuum filtered and the 
precipitate was reserved for further purification (see 3b below). The filtrate was concentrated in 
vacuo. This crude was purified using column chromatography (silica gel, MeOH/DCM 1:99) to 
give 3a as a hard yellow oil (0.067 g, 28%). For 3a:
1
H NMR (400 MHz, DMSO-d6) δ 8.24 (d, J 
= 9.0 Hz, 2H), 7.16 (d, J = 9.1 Hz, 2H), 4.08 (s, 2H), 3.81 (t, J = 6.2 Hz, 2H), 3.62 (t, J = 6.2 Hz, 
3H), 3.40 (t, J = 7.5 Hz, 1H). 
13C NMR (101 MHz, DMSO) δ 171.91, 157.26, 154.50, 143.71, 
125.23, 122.01, 56.89, 44.77, 32.93. MS (ESI) ([M+H]
+
): found 282.05, calculated for 
C11H12N3O4S 282.05. 
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2-((2-hydroxyethyl)imino)-3-(4-nitrophenyl)thiazolidin-4-one (3b) 
The precipitate separated from the crude of 3a was rinsed with THF followed by DCM. The 
solid was then suspended in DCM (10 mL) and triethylamine (0.116 mL, 0.83 mmol) was added 
to neutralize the HBr. The solid dissolved completely after 30 s of sonication. This was washed 
once with water (15 mL) and once with brine (15 mL) and the organic layer was dried over 
MgSO4. The solvent was removed in vacuo to give 3b as a light yellow solid (0.162 g, 69%). For 
3b: 
1
H NMR (300 MHz, DMSO-d6) δ 8.33 (d, J = 9.1 Hz, 2H), 7.64 (d, J = 9.1 Hz, 2H), 4.20 (s, 
2H), 3.47 (t, J = 6.1 Hz, 2H), 3.28 (t, J = 6.1 Hz, 2H);  13C NMR (75 MHz, dmso) δ 170.89, 
147.75, 139.06, 130.26, 124.74, 109.54, 59.40, 52.24, 34.06. MS (ESI) ([M+H]
+
): found 282.05, 
calculated for C11H12N3O4S 282.05. 
 
1-(2-hydroxyethyl)-3-(4-methoxyphenyl)thiourea (4)  
4-methoxyphenyl isothiocyanate (0.211 mL, 1.51 mmol) was dissolved in ethyl acetate (10 mL). 
Ethanolamine (0.0913 mL, 1.51 mmol) was added and the reaction was stirred at room 
temperature for 1 hr. The solvent was removed in vacuo. The crude solid was recrystallized in 
toluene to give 4 as a white powder (0.315 g, 92 %). 
1
H NMR (300 MHz, DMSO-d6) δ 9.41 (s, 
1H), 7.46 (s, 1H), 7.24 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 4.78 (s, 1H), 3.73 (s, 3H), 
3.51 (d, J = 4.8 Hz, 4H); 
13C NMR (75 MHz, dmso) δ 180.81, 156.47, 131.83, 125.73, 113.92, 
59.38, 55.27, 46.5. MS (ESI) ([M+H]
+
): found 227.08,calculated for C10H15N2O2S 227.08.  
 
3-(2-hydroxyethyl)-2-((4-methoxyphenyl)imino)thiazolidin-4-one (4a)  
4 (0.227 g, 1.0 mmol) was dissolved in anhydrous THF (8 mL) and triethylamine (0.140 mL, 1.0 
mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
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(0.0927 mL, 1.0 mmol) in THF (1 mL) was added dropwise within 5 minutes. The reaction was 
stirred at room temperature for 11 hr. The solvent was removed in vacuo and the crude was 
redissolved in DCM (10 mL). Triethylamine (0.140 mL, 1.0 mmol) was added to neutralize the 
HBr that had formed. This was then washed once with water (15 mL) and once with brine (15 
mL). The organic layer was concentrated in vacuo. A column was used to purify the crude (silica 
gel, MeOH/DCM (1:99) to give 4a as an off-white solid (0.159 g, 60 %). 
1
H NMR (300 MHz, 
DMSO-d6) δ 6.90 (q, J = 9.0 Hz, 4H), 3.99 (s, 2H), 3.79 (t, J = 6.4 Hz, 2H), 3.74 (s, 3H), 3.60 (t, 
J = 6.3 Hz, 2H), 3.38 (s, 3H); 
13C NMR (75 MHz, dmso) δ 171.99, 156.04, 154.91, 141.09, 
121.94, 114.46, 56.96, 55.18, 44.62, 32.48. MS (ESI) ([M+H]
+
): found 267.08, calculated for 
C12H15N2O3S 267.07. 
 
1-butyl-3-(2-hydroxyethyl)thiourea (5) 
Butyl isothiocyanate (0.209 mL, 1.74 mmol) was dissolved in ethyl acetate (10 mL). 
Ethanolamine (0.1048 mL, 1.74 mmol) was added. The reaction was stirred at room temperature 
for 16 hr. The reaction was concentrated in vacuo and the crude oil was recrystallized using a 
mixed solvent system of ethyl acetate and cyclohexane to give 5 as a white powder (0.251 g, 82 
%). 
1
H NMR (400 MHz, DMSO-d6) δ 7.48 (s, 1H), 7.31 (s, 1H), 4.76 (s, 1H), 3.65 – 3.39 (m, 
4H), 1.44 (q, J = 7.5 Hz, 2H), 1.38 – 1.18 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, 
DMSO) δ 158.39, 60.14, 55.38, 46.62, 31.36, 20.03, 14.19. MS (ESI) ([M+H]+): found 177.10, 
calculated for C7H17N2OS 177.10. 
 
2-(2-(butylimino)thiazolidin-3-yl)ethan-1-ol (5a) 
5 (0.197 g, 1.12 mmol) was dissolved in anhydrous THF (10 mL) and triethylamine (0.156 mL, 
1.12 mmol) was added. The reaction was stirred for 10 minutes then bromoacetyl bromide (0.098 
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mL, 1.12 mmol) was added dropwise within 5 minutes. The reaction was stirred at room 
temperature for 24 hr. The solvent was removed in vacuo and the crude was purified using 
column chromatography (silica gel, MeOH/DCM 1:99) to give 5a as an oil (0.048 g, 20 %). 
1
H 
NMR (400 MHz, DMSO-d6) δ 4.76 (t, J = 5.9 Hz, 1H), 3.98 (d, J = 7.1 Hz, 2H), 3.65 (t, J = 6.4 
Hz, 2H), 3.62 – 3.54 (m, 1H), 3.49 (q, J = 6.3 Hz, 2H), 3.20 (t, J = 6.7 Hz, 2H), 1.65 – 1.41 (m, 
2H), 1.41 – 1.28 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H).  13C NMR (101 MHz, DMSO) δ 172.10, 
152.60, 57.48, 55.38, 51.42, 44.76, 32.82, 20.42, 14.23. MS (ESI) ([M+H]
+
): found 217.10, 
calculated for C9H17N2O2S 217.09. 
 
1-(1-hydroxypropan-2-yl)-3-(naphthalen-1-yl)thiourea (6) 
1-naphthyl isothiocyanate (0.125 g, 0.675 mmol) was dissolved in ethyl acetate (6 mL). 2-amino-
1-propanol (0.0521 mL, 0.675 mmol) was added and the reaction was stirred at room 
temperature for 16 hr. The solvent was removed in vacuo to give an oil. The crude was 
recrystallized using a mixed solvent system of ethyl acetate and cyclohexane to give 6 as a white 
powder (0.095 g, 54%). 
1
H NMR (300 MHz, DMSO-d6) δ 9.56 (s, 1H), 8.30 – 7.73 (m, 4H), 
7.68 – 7.28 (m, 5H), 4.85 (s, 1H), 4.55 – 4.15 (m, 1H), 3.58 – 3.42 (m, 3H), 1.12 (d, 3H); 13C 
NMR (75 MHz, dmso) δ 181.34, 134.80, 133.96, 129.70, 128.19, 126.37, 126.18, 125.66, 
124.93, 122.84, 63.91, 51.51, 16.98. MS (ESI) ([M+H]+): found 261.10, calculated for 
C14H17N2OS 261.10. 
 
3-(1-hydroxypropan-2-yl)-2-(naphthalen-1-ylimino)thiazolidin-4-one (6a) 
6 (0.095 g, 0.518 mmol) was dissolved in anhydrous THF (5 mL) and triethylamine (0.0722 mL, 
0.518 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
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(0.0479 mL, 0.518 mmol) in THF (1 mL) was added dropwise within five minutes. The reaction 
was stirred at room temperature for 21 hr. Triethylamine (0.0722 mL, 0.518 mmol) was added 
and after stirring for 5 minutes, the solvent was removed in vacuo. The crude was dissolved in 
DCM (10 mL) and washed once with water (15 mL) and once with brine (15 mL) and dried over 
MgSO4. The solvent was removed again and the crude oil was purified using column 
chromatography (silica gel, MeOH/DCM 1:99) to give 6a as a hard oil (0.042 g, 27 %) and 6b 
(0.026 g, 17 %). For 6a: 
1
H NMR (300 MHz, DMSO-d6) δ 10.07 (s, 1H), 8.53 (d, J = 7.1 Hz, 
1H), 8.06 (d, J = 6.2 Hz, 1H), 7.93 (d, J = 3.2 Hz, 1H), 7.72 (dd, J = 28.6, 7.8 Hz, 2H), 7.60 – 
7.32 (m, 3H), 4.21 – 3.99 (m, 1H), 3.89 (s, 2H), 3.70 – 3.51 (m, 2H), 1.18 (d, J = 6.7 Hz, 3H); 
13C NMR (75 MHz, dmso) δ 168.13, 165.49, 134.11, 133.73, 128.59, 128.08, 126.52, 126.34, 
126.01, 125.86, 122.95, 121.88, 48.52, 33.99, 31.13, 19.02. MS (ESI) ([M+H]+): found 301.10, 
calculated for  C16H17N2O2S 301.09.  
 
2-((1-hydroxypropan-2-yl)imino)-3-(naphthalen-1-yl)thiazolidin-4-one (6b) 
Synthesized and purified as stated above (see 6a). For 6b: 
1
H NMR (400 MHz, DMSO-d6) δ 8.04 
(d, J = 8.8 Hz, 2H), 7.76 – 7.51 (m, 4H), 7.48 (d, J = 8.2 Hz, 1H), 4.49 (s, 1H), 4.41 (d, J = 16.9 
Hz, 1H), 4.25 (d, J = 16.9 Hz, 1H), 3.51 (dd, J = 11.3, 5.8 Hz, 1H), 3.27 – 3.10 (m, 1H), 3.08 – 
2.90 (m, 1H), 0.83 (d, J = 6.2 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 206.94, 172.28, 134.31, 
133.02, 130.01, 129.54, 128.75, 127.73, 127.31, 126.82, 126.20, 122.97, 66.41, 60.08, 33.20, 
21.73. MS (ESI) ([M+H]
+
): found 301.10, calculated for  C16H17N2O2S 301.09 
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1-(2-hydroxypropyl)-3-(naphthalen-1-yl)thiourea (7) 
1-naphthyl isothiocyanate (0.125 g, 0.675 mmol) was dissolved in ethyl acetate (6 mL). 1-amino-
2-propanol (0.0521 mL, 0.675 mmol) was added and the reaction was stirred at room 
temperature for 16 hr. The solvent was removed in vacuo. The crude was recrystallized in 
toluene to give 7 as a white powder (0.133 g, 76%).  
1
H NMR (300 MHz, DMSO-d6) δ 9.69 (s, 
1H), 8.11 – 7.73 (m, 3H), 7.73 – 7.33 (m, 5H), 4.76 (s, 1H), 3.83 (m, 1H), 3.56 (m, 1H), 3.31 (m, 
1H), 1.05 (d, J = 6.1 Hz, 3H); 
13C NMR (75 MHz, dmso) δ 182.59, 134.98, 134.36, 130.17, 
128.57, 126.86, 126.59, 126.06, 125.40, 123.20, 65.17, 52.04, 21.64. MS (ESI) ([M+H]
+
): found 
261.10, calculated for C14H17N2OS 261.10. 
 
3-(2-hydroxypropyl)-2-(naphthalen-1-ylimino)thiazolidin-4-one (7a) 
7 (0.066 g, 0.357 mmol) was dissolved in anhydrous THF (5 mL) and triethylamine (0.050 mL, 
0.357 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
(0.034 mL, 0.357 mmol) in THF (1 mL) was added dropwise within five minutes. The reaction 
was stirred at room temperature for 21 hr. Triethylamine (0.050 mL, 0.357 mmol) was added and 
after stirring for 5 minutes, the solvent was removed in vacuo. The crude was dissolved in DCM 
(10 mL) and washed once with water (15 mL) and once with brine (15 mL) and dried over 
MgSO4. The solvent was removed again and the crude oil was purified using column 
chromatography (silica gel, MeOH/DCM 1:99) to give 7a as a hard oil (0.030g, 29 %) and 7b 
(0.012 g, 11 %). For 7a: 
1
H NMR (300 MHz, DMSO-d6) δ 7.91 (d, J = 9.3 Hz, 2H), 7.69 (d, J = 
8.3 Hz, 1H), 7.57 – 7.31 (m, 3H), 7.01 (d, J = 6.2 Hz, 1H), 5.01 (d, J = 5.1 Hz, 1H), 4.37 – 4.10 
(m, 1H), 4.00 (s, 2H), 3.90 (dd, J = 12.2, 8.5 Hz, 1H), 3.72 (dd, J = 13.0, 5.3 Hz, 1H), 1.16 (d, J 
= 6.3 Hz, 3H). 
13C NMR (75 MHz, dmso) δ 172.69, 156.80, 145.09, 134.38, 128.33, 127.28, 
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126.87, 126.40, 126.13, 124.56, 123.66, 115.64, 63.38, 50.18, 33.00, 21.53. MS (ESI) ([M+H]
+
): 
found 301.10, calculated for  C16H17N2O2S 301.09. 
 
2-((2-hydroxypropyl)imino)-3-(naphthalen-1-yl)thiazolidin-4-one (7b) 
Synthesized and purified as stated above (7a). For 7b: 
1
H NMR (400 MHz, DMSO-d6) δ 8.03 (d, 
J = 8.3 Hz, 2H), 7.70 – 7.51 (m, 4H), 7.48 (d, J = 8.3 Hz, 1H), 4.55 (t, J = 5.7 Hz, 1H), 4.40 (d, J 
= 16.9 Hz, 1H), 4.25 (d, J = 16.9 Hz, 1H), 3.40 – 3.23 (m, 1H), 3.23 – 3.03 (m, 2H), 0.86 (d, J = 
6.3 Hz, 3H).  
13
C NMR (101 MHz, DMSO) δ 172.30, 152.56, 134.34, 133.04, 129.95, 129.49, 
128.76, 127.79, 127.28, 126.80, 126.24, 122.98, 66.42, 60.36, 32.95, 18.28. MS (ESI) ([M+H]
+
): 
found 301.10, calculated for  C16H17N2O2S 301.09. 
 
1-(3-hydroxypropyl)-3-(naphthalen-1-yl)thiourea (8) 
1-naphthyl isothiocyanate (0.300 g, 1.62 mmol) was dissolved in ethyl acetate (8 mL). 3-amino-
1-propanol (0.126 mL, 1.62 mmol) was added. The reaction was stirred at room temperature for 
16 hr. The solvent was removed in vacuo. The crude was recrystallized in toluene to give 8 as a 
white powder (0.322 g, 76 %). 
1
H NMR (300 MHz, DMSO-d6) δ 9.58 (s, 1H), 7.90 (dd, J = 34.7, 
6.3 Hz, 3H), 7.77 – 7.28 (m, 5H), 4.40 (s, 1H), 3.75 – 3.05 (m, 4H), 1.82 – 1.39 (m, 2H); 13C 
NMR (75 MHz, dmso) δ 181.61, 134.36, 133.96, 129.85, 128.06, 126.62, 126.12, 125.69, 
125.07, 122.84, 58.61, 31.72, 30.65. MS (ESI) ([M+H]
+
): found 261.10, calculated for 
C14H17N2OS 261.10. 
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3-(3-hydroxypropyl)-2-(naphthalen-1-ylimino)thiazolidin-4-one (8a) 
8 (0.191 g, 0.734 mmol) was dissolved in anhydrous THF (6 mL) and triethylamine (0.102 mL, 
0.734 mmol) was added. The mixture was stirred for 10 minutes. Bromoacetyl bromide (0.0678 
mL, 0.734 mmol) in THF (1 mL) was added dropwise within 5 minutes. The reaction was stirred 
at room temperature for 24 hr. The precipitate was collected by gravity filtration and rinsed with 
DCM. This gummy solid was reserved for purification (see 8b below). The filtrate was 
concentrated in vacuo. The crude was dissolved in DCM (10 mL) and washed once with water 
(15 mL) and once with brine (15 mL). The organic layer was concentrated and purified by 
column chromatography (silica gel, MeOH/DCM 1:99) to give 8a as a yellow oil (0.0817 g, 37 
%). For 8a: 
1
H NMR (300 MHz, DMSO-d6) δ 10.07 (s, 1H), 8.46 (s, 1H), 8.19 – 7.85 (m, 2H), 
7.73 (dd, J = 26.0, 7.7 Hz, 2H), 7.60 – 7.40 (m, 3H), 3.89 (s, 2H), 3.48 (d, J = 29.7 Hz, 4H), 2.17 
– 1.76 (m, 2H). 13C NMR (75 MHz, dmso) δ 168.15, 165.84, 134.12, 133.79, 128.58, 128.06, 
126.50, 126.33, 126.00, 125.81, 122.97, 121.80, 39.75, 34.03, 32.70, 32.48. MS (ESI) ([M+H]
+
): 
found 301.10, calculated for C16H17N2O2S 301.09. 
 
2-((3-hydroxypropyl)imino)-3-(naphthalen-1-yl)thiazolidin-4-one (8b) 
The precipitate from 8a (above) was suspended in DCM (10 mL) and triethylamine (0.102 mL, 
0.734 mmol) was added. After sonication, all of the solid dissolved. The organic solution was 
washed once with water (15 mL) and once with brine (15 mL) and dried over MgSO4. The DCM 
was removed in vacuo to give 8b as a yellow oil (0.0781 g, 36 %). 
1
H NMR (300 MHz, DMSO-
d6) δ 8.03 (d, J = 8.6 Hz, 2H), 7.88 – 7.30 (m, 5H), 4.49 – 4.08 (m, 3H), 3.26 – 3.01 (m, 4H), 
1.66 – 1.37 (m, 2H). 13C NMR (75 MHz, dmso) δ 172.19, 153.28, 134.30, 133.01, 130.00, 
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129.52, 128.73, 127.65, 127.34, 126.82, 126.17, 122.90, 48.89, 33.65, 33.16, 29.47. MS (ESI) 
([M+H]
+
): found 301.10, calculated for C16H17N2O2S 301.09. 
 
1-(4-hydroxybutyl)-3-(naphthalen-1-yl)thiourea (9) 
1-naphthyl isothiocyanate (0.200 g, 1.08 mmol) was dissolved in ethyl acetate (10 mL). 4-amino-
1-butanol (0.995 mL, 1.08 mmol) was added and the reaction was stirred at room temperature for 
16 hr. The solvent was removed in vacuo. The crude was recrystallized in toluene to give 9 as a 
white solid (0.1756 g, 52 %). 
1
H NMR (300 MHz, DMSO-d6) δ 9.54 (s, 1H), 8.20 – 7.75 (m, 
3H), 7.75 – 7.39 (m, 5H), 4.38 (s, 1H), 3.66 – 3.36 (m, 4H), 1.73 – 1.20 (m, 4H). 13C NMR (75 
MHz, dmso) δ 182.07, 134.86, 134.43, 130.34, 128.54, 127.03, 126.57, 126.17, 125.52, 123.32, 
60.96, 44.50, 30.30, 25.86. MS (ESI) ([M+H]
+
): found 275.12, calculated for C15H19N2OS 
275.11. 
 
3-(4-hydroxybutyl)-2-(naphthalen-1-ylimino)thiazolidin-4-one (9a) 
9 (0.301 g, 1.09 mmol) was dissolved in anhydrous THF (10 mL) and triethylamine (0.153 mL, 
1.09 mmol) was added. Bromoacetyl bromide (0.096 mL, 1.09 mmol) in THF (1 mL) was added 
dropwise within 5 minutes. The reaction was stirred at room temperature for 24 hr. The solvent 
was removed in vacuo. The crude was purified using column chromatography (silica gel, 
MeOH/DCM 1:99) to give 9a as a clear oil (0.095 g, 28 %) as well as 9b as a clear oil (0.065 g, 
19 %). For 9a: 
1
H NMR (300 MHz, DMSO-d6) δ 8.04 – 7.81 (m, 2H), 7.69 (d, J = 8.3 Hz, 1H), 
7.63 – 7.37 (m, 3H), 7.02 (d, J = 8.3 Hz, 1H), 4.48 (t, J = 5.1 Hz, 1H), 4.03 (s, 2H), 3.88 (t, J = 
7.2 Hz, 2H), 3.47 (q, J = 7.8, 7.1 Hz, 2H), 1.93 – 1.63 (m, 2H), 1.63 – 1.38 (m, 2H). 13C NMR 
(75 MHz, dmso) δ 172.53, 156.39, 144.99, 134.39, 128.37, 127.28, 126.87, 126.39, 126.21, 
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124.62, 123.49, 115.67, 60.80, 42.96, 32.97, 30.30, 24.19. MS (ESI) ([M+H]
+
): found 315.11, 
calculated for C17H19N2O2S 315.11.  
  
2-((4-hydroxybutyl)imino)-3-(naphthalen-1-yl)thiazolidin-4-one (9b) 
Synthesized and purified as stated above (see 9a). For 9b: 
1
H NMR (300 MHz, DMSO-d6) δ 8.02 
(d, J = 8.4 Hz, 2H), 7.79 – 7.29 (m, 5H), 4.55 – 4.08 (m, 3H), 3.24 – 2.90 (m, 4H), 1.45 – 1.11 
(m, 4H). 
13C NMR (75 MHz, dmso) δ 172.20, 153.02, 134.29, 133.04, 130.00, 129.51, 128.73, 
127.64, 127.33, 126.82, 126.18, 122.91, 60.80, 51.87, 33.10, 30.56, 26.99. MS (ESI) ([M+H]
+
): 
found 315.11, calculated for C17H19N2O2S 315.11. 
 
1-(4-bromophenyl)-3-propylthiourea (10) 
4-Bromophenyl isothiocyanate (0.400 g, 1.87 mmol) was dissolved in ethyl acetate (10 mL). 
Propylamine (0.1536 mL, 1.87 mmol) was added and the reaction was stirred at room 
temperature for 3 hr. The solvent was removed in vacuo. The crude NMR showed a pure product 
with no starting material left, so the product was used without further purification. 10 was 
produced as a hard oil (0.498 g, 98 %). 
1
H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 7.84 (s, 
1H), 7.47 (d, J = 8.9 Hz, 2H), 7.41 (d, J = 8.9 Hz, 2H), 3.41 (s, 2H), 1.54 (h, J = 7.4 Hz, 2H), 
0.88 (t, J = 7.4 Hz, 3H). 
13
C NMR (101 MHz, DMSO) δ 180.77, 139.37, 131.71, 125.15, 116.16, 
46.05, 22.17, 11.87. MS (ESI) ([M+H]
+
): found 273.0 and 275.0, calculated for C10H14BrN2S 
273.00. 
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2-((4-bromophenyl)imino)-3-propylthiazolidin-4-one (10a) 
10 (0.050 g, 0.183 mmol) was dissolved in acetonitrile (5 mL) and triethylamine (0.0255 mL, 
0.183 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
(0.0169 mL, 0.183 mmol) in acetonitrile (1 mL) was added dropwise within 5 minutes. The 
reaction was stirred at room temperature for 6 hr. The solvent was concentrated in vacuo and 
then dissolved in DCM (10 mL). Triethylamine (0.0255 mL, 0.183 mmol) was added. The 
product was purified by column chromatography (silica gel, eluted with 100 % DCM)) to give 
10a (0.005 g, 9 %) and 10b as a yellow oil (0.045 g, 79 %). For 10a: 
1
H NMR (400 MHz, 
DMSO-d6) δ 7.53 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 4.05 (s, 2H), 3.68 (t, J = 7.0 Hz, 
2H), 1.64 (h, J = 7.4 Hz, 2H), 0.89 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 172.44, 
156.55, 148.01, 132.62, 123.68, 116.87, 44.31, 33.06, 20.50, 11.64. . MS (ESI) ([M+H]
+
): found 
312.99 and 314.99, calculated for C12H14BrN2OS 312.99 
 
3-(4-bromophenyl)-2-(propylimino)thiazolidin-4-one (10b) 
Synthesized and purified as stated above (see 10a). For  10b: 
1
H NMR (400 MHz, DMSO-d6) δ 
7.67 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 4.13 (s, 2H), 3.14 (t, J = 6.8 Hz, 2H), 1.47 (h, 
J = 7.2 Hz, 2H), 0.82 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 171.71, 152.84, 
135.36, 132.29, 131.11, 121.69, 53.57, 32.98, 23.77, 12.28. MS (ESI) ([M+H]
+
): found 312.99 
and 314.99, calculated for C12H14BrN2OS 312.99. 
 
1-(naphthalen-1-yl)-3-propylthiourea (11) 
1-Naphthyl isothiocyanate (0.151 g, 0.817 mmol) was dissolved in ethyl acetate. Propylamine 
(0.067 mL, 0.817 mmol) was added and the reaction was stirred at room temperature for 16 hrs. 
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The crude was washed with 1 M HCl (2x), once with brine, and dried over MgSO4. The solvent 
was removed in vacuo to give the product 11 as a pale yellow solid in quantitative yield. 
1
H 
NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H), 7.97 (d, J = 9.4 Hz, 1H), 7.87 (t, J = 9.6 Hz, 2H), 
7.68 – 7.37 (m, 5H), 3.40 (q, J = 6.5 Hz, 2H), 1.67 – 1.44 (m, 2H), 0.83 (t, J = 7.0 Hz, 3H). 13C 
NMR (101 MHz, DMSO) δ 182.15, 134.93, 134.46, 130.36, 128.57, 127.09, 126.61, 126.21, 
125.54, 123.34, 46.35, 22.38, 11.78. MS (ESI) ([M+H]
+
): found 245.10, calculated for  
C14H17N2S 245.10. 
 
2-(naphthalen-1-ylimino)-3-propylthiazolidin-4-one (11a) 
11 (0.100 g, 0.54 mmol) was dissolved in THF (5 mL). Triethylamine (0.075 mL, 0.54 mmol) 
was added and the reaction was stirred for 5 min. Bromoacetyl bromice (0.050 mL, 0.54 mmol) 
was added. The reaction was stirred at room temperature for 16 hours. The solvent was removed 
in vacuo. DCM (10 mL) was added and the crude was washed with a solution of sodium 
bicarbonate (pH 8) and dried over MgSO4. The organic layer was concentrated in vacuo and 
purified via column chromatography (silica gel, 0.5% EtOAC and 99.5% DCM eluting solvent) 
to give 11a (0.02 g, 17%) and 11b (0.07 g, 60 %) For 11a: 
1
H NMR (400 MHz, DMSO-d6) δ 
7.94 (d, J = 7.3 Hz, 1H), 7.88 (d, J = 8.6 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.64 – 7.39 (m, 3H), 
7.04 (d, J = 8.3 Hz, 1H), 4.06 (s, 2H), 3.86 (t, J = 6.9 Hz, 2H), 1.80 (h, J = 7.4 Hz, 2H), 0.99 (t, J 
= 7.5 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 172.59, 156.49, 145.02, 134.42, 128.42, 127.30, 
126.89, 126.43, 126.24, 124.65, 123.44, 115.70, 44.54, 33.01, 20.78, 11.75. MS (ESI) ([M+H]
+
): 
found 285.10, calculated for C16H17N2OS 285.10 
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3-(naphthalen-1-yl)-2-(propylimino)thiazolidin-4-one (11b) 
Synthesized and purified as stated above (see 11a). For 11b: 
1
H NMR (400 MHz, DMSO-d6) δ 
8.04 (d, J = 8.4 Hz, 2H), 7.75 – 7.51 (m, 4H), 7.46 (d, J = 7.3 Hz, 1H), 4.40 (d, J = 16.9 Hz, 1H), 
4.25 (d, J = 16.9 Hz, 1H), 3.24 – 3.01 (m, 2H), 1.47 – 1.26 (m, 2H), 0.71 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, DMSO) δ 172.24, 153.09, 134.33, 133.09, 130.03, 129.54, 128.76, 127.68, 
127.34, 126.84, 126.21, 122.94, 53.63, 33.15, 23.63, 12.09. MS (ESI) ([M+H]
+
): found 285.10, 
calculated for C16H17N2OS 285.10 
 
3-(2-hydroxyethyl)-5-methyl-2-(naphthalen-1-ylimino)thiazolidin-4-one (12) 
4-Bromophenyl thiourea (2) (0.200 g, 0.753 mmol) was dissolved in anhydrous THF (8 mL) and 
triethylamine (0.105 mL, 0.753 mmol) was added. The mixture was stirred for 10 minutes then 
bromoacetyl bromide (0.0790 mL, 0.753 mmol) in THF (1 mL) was added dropwise within 5 
minutes. The reaction was stirred at room temperature for 24 hr. The solvent was removed in 
vacuo and the crude was dissolved in DCM (15 mL). The organic layer was washed once with 
water (15 mL), once with 1 M HCl (15 mL), and once with brine (15 mL). The organic layer was 
concentrated in vacuo and purified by column chromatography (silica gel, MeOH/DCM 1:99) to 
yield the product 12 as a white powder (0.067 g, 27%). 
1
H NMR (400 MHz, DMSO-d6) δ 7.53 
(d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 2H), 4.81 (s, 1H), 4.34 (q, J = 7.2 Hz, 1H), 3.80 (t, J = 
7.0 Hz, 2H), 3.61 (t, J = 6.3 Hz, 2H), 1.50 (d, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 
175.52, 155.34, 148.00, 132.56, 123.71, 116.87, 57.39, 45.21, 42.67, 19.21.  MS (ESI) 
([M+H]
+
): found 328.99 and 330.99, calculated for  C12H14BrN2O2S 328.99. 
 
 
 
97 
 
 
2-(naphthalen-1-ylamino)-2-oxoethyl) (2-bromoethyl)carbamothioate (13) 
The solid precipitate formed in the reaction of 1 with BrAcBr (crude 1b HBr salt) (0.023 g, 0.06 
mmol) was dissolved in acetonitrile (3 mL) and heated to 65°C.  The reaction was run for 5 hr 
then concentrated in vacuo. The crude was purified by column chromatography (silica gel, 
MeOH/DCM 0.5:99.5) to give the product as a pale yellow oil (0.006 g, 26 %). 
1
H NMR (400 
MHz, DMSO-d6) δ 10.08 (s, 1H), 8.69 (s, 1H), 8.16 – 8.00 (m, 1H), 8.00 – 7.88 (m, 1H), 7.77 (d, 
J = 8.2 Hz, 1H), 7.69 (d, J = 7.3 Hz, 1H), 7.63 – 7.40 (m, 3H), 3.92 (s, 2H), 3.62 – 3.48 (m, 4H). 
13C NMR (101 MHz, DMSO) δ 168.01, 166.26, 134.14, 133.80, 128.60, 128.07, 126.52, 126.33, 
126.03, 125.83, 123.03, 121.84, 55.39, 34.09, 32.42. MS (ESI) ([M+H]
+
): found 367.01 and 
369.00, calculated for C15H16BrN2O2S 367.00. 
 
2-(naphthalen-1-ylamino)-2-oxoethyl) (2-chloroethyl)carbamothioate (14) 
1b (0.015 g, 0.0524 mmol) was dissolved in acetonitrile (3 mL) and heated to 60°C. Enough HCl 
was added to give the reaction a pH of 4, checked using litmus paper. The reaction was run for 
16 hr then concentrated in vacuo. The crude was purified by column chromatography (silica gel, 
MeOH/DCM 1:9) to give the product as a pale yellow oil (0.0145 g, 86%). 
1
H NMR (300 MHz, 
DMSO-d6) δ 10.10 (s, 1H), 8.67 (s, 1H), 8.15 – 8.01 (m, 1H), 8.01 – 7.85 (m, 1H), 7.77 (d, J = 
8.2 Hz, 1H), 7.68 (d, J = 7.3 Hz, 1H), 7.62 – 7.39 (m, 3H), 3.91 (s, 2H), 3.66 (t, J = 6.0 Hz, 2H), 
3.48 (q, J = 5.8 Hz, 2H); 
13C NMR (75 MHz, dmso) δ 168.00, 166.28, 134.11, 133.77, 128.58, 
128.04, 126.51, 126.31, 126.01, 125.80, 123.01, 121.83, 43.67, 43.09, 34.04. MS (ESI) 
([M+H]
+
): found 323.06, calculated for  C15H16ClN2O2S 323.05. 
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2-(naphthalen-1-ylamino)-2-oxoethyl) (1-bromopropan-2-yl)carbamothioate (15) 
1-naphthyl isothiocyanate (0.100 g, 0.54 mmol) was dissolved in THF (5 mL) and 2-amino-1-
propanol (0.043 mL, 0.54 mmol) was added. The reaction was stirred at room temperature for 2 
hrs. After this time, triethylamine (0.0752 mL, 0.54 mmol) was added, followed by bromoacetyl 
bromide (0.050 mL, 0.54 mmol) after waiting a period of 5 min. The reaction was stirred at room 
temperature for 14 hrs then heated to 65C for an additional 8 hrs. The solvent was removed in 
vacuo. The crude was purified using column chromatography (silica gel, 1:99 MeOH/DCM) to 
give the product as a slightly yellow hard oil (0.052 g, 25 % yield). 
1
H NMR (400 MHz, DMSO-
d6) δ 10.10 (s, 1H), 8.56 (d, J = 7.0 Hz, 1H), 8.10 (d, J = 9.5 Hz, 1H), 7.94 (t, J = 8.5 Hz, 1H), 
7.78 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 7.3 Hz, 1H), 7.61 – 7.47 (m, 4H), 4.17 – 4.02 (m, 1H), 3.92 
(s, 2H), 3.64 – 3.47 (m, 2H), 1.20 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 168.11, 
165.49, 134.15, 133.81, 128.61, 128.07, 126.52, 126.33, 126.03, 125.82, 123.01, 121.83, 48.54, 
38.42, 34.07, 19.05. MS (ESI) ([M+H]
+
): found 381.0 and 383.0 (10% intensity) and ([M+Na]
+
) 
403.00 and 405.00 (100% intensity), calculated for C16H18BrN2O2S 381.02. 
 
2-((4-bromophenyl)amino)-2-oxoethyl) (2-bromoethyl)carbamothioate (16) 
2b (0.015 g, 0.0478 mmol) was dissolved in acetonitrile (2 mL) and heated to 65°C. Enough HBr 
was added to give the reaction a pH of 4, checked using litmus paper. The reaction was run for 
24 hr then concentrated in vacuo. The crude was purified by column chromatography (silica gel, 
DCM 100%) to give the product as a pale yellow oil (0.0124 g, 66 %). 
1
H NMR (400 MHz, 
DMSO-d6) δ 10.30 (s, 1H), 8.64 (s, 1H), 7.56 (d, J = 9.0 Hz, 2H), 7.49 (d, J = 8.9 Hz, 2H), 3.76 
(s, 2H), 3.50 (s, 4H); 
13C NMR (101 MHz, DMSO) δ 167.29, 165.93, 138.80, 132.04, 121.44, 
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115.37, 43.05, 34.49, 32.37. MS (ESI) ([M+H]
+
): found 394.90 (50%), 396.90 (100%), and 
398.90 (50%), calculated for C11H13Br2N2O2S 394.90. 
  
Treatment of 1b to decyclization conditions 
1b (0.022 g, 0.08 mmol) was dissolved in acetonitrile (3 mL). Concentrated HCl (10 uL) was 
added and the reaction was stirred at 65C for 24 hours. There was little significant change in the 
NMR taken of the crude reaction and ESI MS showed the ring (([M+H]
+
): 287) but no peak for 
what would be the product (([M+H]
+
): 322).  
 
Treatment of 10b to decyclization conditions 
A small amount of the crude reaction mixture of 10b (0.0317 g,) was dissolved in THF (3 mL) 
with a drop of water added. The mixture was heated at 60°C for 24 hr. The solvent was removed 
in vacuo and an NMR was taken of this crude. The NMR indicated that there was no change in 
the composition of the products when refluxed in the presence of 1 mol. eq. of HBr that forms 
during the course of the reaction. 
 
Crude brph -78 to reflux with and without base 
2 (0.075 g, 0.273 mmol) was dissolved in THF (4 mL) and triethylamine (0.038 mL, 0.273 
mmol) was added. The mixture was cooled to -78°C using an acetone/dry ice bath. Bromoacetyl 
bromide (0.0252 mL, 0.273 mmol) was added. The reaction was stirred at -78°C for 6 hr. At this 
time, a portion of the reaction (200 uL) was removed for an NMR. The rest of the reaction was 
allowed to stir at room temperature for 0.5 hr then heated to 60°C. The reaction was run at this 
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temperature for 16 hr. The solvent was removed in vacuo and some of the crude was taken for 
another NMR. Comparison of the NMRs shows that 2b formed and then reacted to form 16. 
 
2 (0.013 g, 0.0472 mmol) was dissolved in acetonitrile (3 mL). Triethylamine (0.01975 mL, 
0.1416 mmol) was added. The reaction was cooled to -10°C using a salt/ice bath. Bromoacetyl 
bromide (0.00437 mL, 0.0472 mmol) was added. The reaction was stirred for 6 hr. At this time, 
some of the mixture was removed for an NMR while the rest was heated up to 60°C. The 
reaction was stirred at this temperature for 16 hr. The solvent was removed in vacuo and an 
NMR of the crude was taken.  
 
Temperature study of product distribution of 10a and 10b formed at -45°C 
10 (0.050 g, 0.183 mmol) was dissolved in acetonitrile (5 mL) and triethylamine (0.0255 mL, 
0.183 mmol) was added. The mixture was stirred for 10 minutes and then bromoacetyl bromide 
(0.0169 mL, 0.183 mmol) in acetonitrile (1 mL) was added dropwise within 5 minutes. The 
reaction was stirred in an acetonitrile/dry ice bath (-45C) for 6 hr. The crude reaction was treated 
in the same manner as above to yield 10b (0.042 g, 73 %) and 10a (0.003 g, 5 %). 
 
Study of the effects of different solvents on product distribution 
1 (0.025 g, 0.102 mmol) was dissolved in 2 mL of the chosen solvent. The solvents used were 
acetone, acetonitrile, THF, ethyl acetate, DCM, or benzene. Triethylamine (0.0141 mL, 0.102 
mmol) was added with stirring followed by bromoacetyl bromide (0.0094 mL, 0.102 mmol). The 
reactions were stirred at room temperature for 19 hrs. The solvent was removed in vacuo. Each 
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crude reaction was dissolved in DCM (1 mL) and washed with sat. NaHCO3. 250 uL of the 
organic layer was removed, dried, and dissolved in 500 uL of DMSO-d6 for NMR.  
 
The same procedure was followed using 11 (0.025 g, 0.102 mmol) and the same set of solvents. 
 
One-pot multi-step synthesis series 
Bromophenyl isothiocyanate (0.100 g, 0.509 mmol) was dissolved in THF (5 mL). Ethanolamine 
(0.0307 mL, 0.509 mmol) was added and the reaction was stirred at room temperature for 19 hrs. 
200 uL of the reaction mixture was removed for NMR. Triethylamine (0.071 mL, 0.509 mmol) 
was added and the reaction was cooled to -78C using an acetone/dry ice bath. Bromoacetyl 
bromide (0.0444 mL, 0.509 mmol) was added and the reaction was stirred for 6 hrs at -78C. 200 
uL of the reaction mixture was removed for NMR. The reaction was allowed to stir for 30 min at 
room temperature then heated to 65C on an oil bath. The reaction stirred at this temperature for 4 
hrs. After this time, 200 uL of the reaction mixture was removed for NMR and the reaction was 
stopped by removing the solvent in vacuo. 
 
The same procedure was followed for the second series with one difference. After the addition of 
triethylamine, the reaction was kept at room temperature for the addition of bromoacetyl bromide 
and for the six hrs of reaction time, followed by 4 hrs of heating at 65C. 
 
HSQC and HMBC analysis 
1a (16 mg) and 1b (22 mg) were each dissolved in 0.6 mL of DMSO-d6. A H NMR (16 scans), C 
NMR (1024 scans), HSQC (8 scans, expt HSQCGP), and HMBC (32 scans, expt HMBCGPND) 
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were taken for each of the samples. NMRS were run on a Bruker NanoBay AVANCE III 400 
MHz running TopSpin 3.2 using the default experimental settings.  
 
Crystallization of samples for single crystal x-ray analysis 
The same general procedure was followed for growing crystals of 1a, 8a, 15, and 16: 17-20 mg 
of the sample was dissolved in 0.5 mL of DCM in a 4 mL vial. This was placed into a 10 mL vial 
containing 2 mL of cyclohexane and the cap of the outer vial was secured and covered with 
parafilm. The samples were allowed to sit undisturbed for 2 weeks. 16 was crystallized using 
THF instead of DCM. 5a was crystallized by dissolving 20 mg in 0.5 mL DCM and heating. 
Cyclohexane was added until the solution turned cloudy (1.5 mL) The sample was heated again 
until clear and then the cap was secured and covered with parafilm. The sample was left 
undisturbed for 2 weeks. 
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